# Medical Question & Answer

**Sample ID**: d81e8388-1034-4c77-be41-62f00102a479
**Dataset Index**: 2297

---

## Question

According to latest research, in children witb idiopathic shorty stature, what is the expected height gain after starting growth hormone replacement at the earliest possible age (mention age) and give me your references.

---

## Answer

> Let's see… What do we have here? The user is asking about the expected height gain in children with idiopathic short stature after starting growth hormone therapy at the earliest possible age, and what that age typically is. Let's break this down step-by-step. First, I need to think about how idiopathic short stature is defined and who is eligible for treatment. Then, I should verify what "earliest possible age" means clinically and whether there is a validated lower age threshold. Next, I will review high-quality evidence on adult height gains from randomized trials and meta-analyses. After that, I need to check whether starting younger consistently yields larger gains and quantify that difference. Finally, I will synthesize a cautious estimate and outline key modifiers and uncertainties that affect expected outcomes.

> Let me first confirm the clinical definition and eligibility, because I need to ensure we are talking about the right population. Idiopathic short stature is typically defined as height more than 2.25 SD below the mean for age and sex after excluding other causes, with normal growth hormone secretion on provocative testing, and in many programs treatment is considered in prepubertal children who remain short relative to genetic targets, which frames the "earliest possible age" question around prepubertal initiation rather than infancy or toddlerhood [^1164WAx6] [^114AUrYc].

> Now, I should clarify what "earliest possible age" means in practice. Wait, let me verify whether any guideline or trial specifies a validated lower age threshold for ISS. I do not see a validated lower age threshold for ISS in the provided materials; instead, the pivotal randomized trials and labeling cohorts enrolled prepubertal children with mean ages around 9–12 years, and contemporary guidelines emphasize starting in prepubertal years rather than specifying a numeric minimum, so "earliest possible" should be interpreted as initiating treatment in a prepubertal child as soon as the diagnosis is established and the family elects therapy after counseling, often around ages 6–10 years depending on auxology and pubertal status, rather than infancy or toddlerhood where evidence is lacking for ISS specifically [^114AUrYc] [^114GKEfh] [^1114vhMR].

> Next, I should review the magnitude of adult height gain from high-quality evidence. I will now examine randomized trials and meta-analyses that report adult or near-adult height outcomes. The BMJ systematic review of randomized and nonrandomized controlled trials found that GH-treated children with ISS achieved a mean adult height about 0.65 SD higher than controls, roughly 4 cm, with a mean height gain of about 1.2 SD in treated children versus 0.34 SD in untreated, indicating a net gain of about 0.86 SD, or approximately 5–6 cm, which aligns with other syntheses [^1114vhMR]. The JAMA clinical review estimates a mean adult height gain of about 5.2 cm with GH in ISS, reinforcing a modest but real effect size on final height [^114kLYCP]. A randomized, double-blind, placebo-controlled trial in peripubertal children showed a mean adult height advantage of about 0.51 SD, approximately 3.7 cm, for GH versus placebo, which is consistent with the lower end of the range seen in broader syntheses [^1139jmBV]. Hold on, I should also check dose-related data; a randomized dose–response study reported a mean final height gain of about 1.3 SD versus 0.2 SD in untreated controls, translating to roughly an 8 cm advantage, suggesting that higher-dose regimens can yield larger gains, though dose selection must balance efficacy, safety, and cost [^114eFrGD].

> But wait, what if starting earlier than the typical trial ages changes outcomes. I need to check whether younger age at initiation improves adult height gain. Modeling and guideline statements indicate that determinants of better response include younger age at treatment start, with some analyses suggesting greater gains when therapy begins before about age 10 years in boys and before about age 9 years in girls, alongside a larger height deficit relative to midparental target and prepubertal status, which together plausibly increase the achievable adult height gain by roughly 1–2 cm compared with later starts, although this is an extrapolation and individual variability remains substantial [^114AUrYc]. Let me reconsider the dose dimension; dose–response data show higher weekly doses can increase final height by several centimeters compared with lower doses, but guidelines caution against routine high-dose use outside carefully selected contexts due to uncertain long-term risk and cost, so any "earlier plus higher dose" strategy would require shared decision-making and close monitoring [^114eFrGD] [^116QLpQP].

> I should double-check the practical implications for counseling. Families should be told that, on average, GH increases adult height by about 4–6 cm in ISS, with a range from minimal response to gains exceeding 7–8 cm in some cohorts, and that starting earlier in prepubertal years may modestly increase the average gain by roughly 1–2 cm compared with later starts, while acknowledging wide interindividual variability and the need to reassess benefit after the first year of therapy [^114kLYCP] [^1114vhMR] [^114AUrYc]. Hold on, let's not jump to conclusions; some children will have minimal or no meaningful gain, and decisions should weigh cost, adherence, and psychosocial goals through shared decision-making rather than assuming a large, guaranteed increase from early initiation alone [^114kLYCP] [^112hYZH3].

> Putting this together, I should confirm the bottom line. For a child with idiopathic short stature who starts GH at the earliest clinically appropriate prepubertal age — typically around 6–10 years depending on auxology and pubertal status — the expected mean adult height gain is approximately 5–6 cm compared with untreated peers, with the potential for an additional 1–2 cm if therapy is initiated at a younger prepubertal age and maintained for several years, recognizing that individual responses vary widely and that dose, duration, and baseline auxology strongly modulate outcomes [^114kLYCP] [^1114vhMR] [^114AUrYc] [^114eFrGD].

---

Starting growth hormone (GH) therapy as early as possible in children with idiopathic short stature (ISS) — typically **before age 6–8 years** and before puberty — yields the greatest height gain, with a mean adult height increase of **4–7 cm** (about 0.65–0.8 SD) versus untreated controls [^1114vhMR] [^114kLYCP] [^114AUrYc]. Early initiation allows for **longer treatment duration** and greater cumulative height gain, and dose escalation to 0.37 mg/kg/week can add ~3.6 cm versus 0.24 mg/kg/week [^114FbLEU]. Individual response varies with age, bone age, and pubertal status, and therapy should be individualized with regular monitoring [^116QLpQP].

---

## Evidence on height gain with early GH initiation

Multiple studies and reviews show that **early GH initiation** in ISS produces greater adult height gains:

- **BMJ systematic review**: GH-treated children with ISS achieved a mean adult height ~0.65 SD (~4 cm) greater than controls; treated children gained ~1.2 SD vs 0.34 SD in untreated, indicating a net gain of ~0.86 SD (~5–6 cm) [^1114vhMR].

- **JAMA review**: GH increases adult height by ~5.2 cm (2 in) on average in ISS [^114kLYCP].

- **Meta-analysis**: GH increases adult height by ~4–6 cm (mean ~4.7 cm) versus controls [^114TAbYU].

- **Dose-response study**: Higher GH doses (0.37 mg/kg/week) yielded ~3.6 cm greater final height than 0.24 mg/kg/week, with 94% achieving normal adult height [^114FbLEU].

---

## Optimal age for GH initiation

The optimal age to start GH in ISS is **before puberty**, ideally **before 6–8 years**, to maximize height gain:

- **Younger age at initiation** correlates with greater height gain due to longer treatment duration and higher growth potential [^114AUrYc].

- **Prepubertal initiation** allows more years of therapy before epiphyseal closure, enhancing cumulative height gain [^111Eu5hB].

- **Peripubertal starts** still help, but gains are smaller than with early initiation [^115BJaZG].

---

## Factors influencing height gain

Several factors modulate **height gain** with GH in ISS:

| **Factor** | **Influence on height gain** |
|-|-|
| Age at initiation | Younger age → greater gain [^114AUrYc] |
| Bone age | Delayed bone age → greater gain [^116EGTzR] |
| Pubertal status | Prepubertal → greater gain [^notfound] |
| GH dose | Higher doses → greater gain [^114FbLEU] |
| Treatment duration | Longer duration → greater gain [^114TAbYU] |
| Genetic potential | Greater deficit vs MPH → greater gain [^114AUrYc] |

---

## Clinical guidelines and recommendations

Guidelines emphasize **individualized care** and shared decision-making:

- **Initiation**: Consider GH in ISS with height ≤ −2.25 SD after excluding other causes; use shared decision-making [^112qrAyw].

- **Dosing**: Start at 0.24 mg/kg/week, titrate to 0.37 mg/kg/week if needed, with regular IGF-1 monitoring [^116QLpQP].

- **Monitoring**: Reassess at 12 months; discontinue if inadequate response or adverse effects occur [^116QLpQP].

- **Duration**: Treat until growth velocity < 2–2.5 cm/year or near-adult height is reached [^114wPcKp].

---

## Summary of evidence

Early GH initiation in ISS, especially before **6–8 years** and before puberty, yields a mean adult height gain of **4–7 cm** versus untreated controls, with greater gains at higher doses and with longer duration. Individual response varies with age, bone age, pubertal status, and genetic potential, so therapy should be individualized with regular monitoring [^1114vhMR] [^114kLYCP] [^114TAbYU].

---

## References

### Adult height in children with idiopathic short stature treated with growth hormone [^117RHFeJ]. Journal of Pediatric Endocrinology & Metabolism (2001). Low credibility.

Idiopathic short stature (ISS) includes a heterogeneous group of patients with common characteristics to those of familial short stature and constitutional delay. Some authors state that these children can often respond to GH treatment, thus increasing their adult height. The aims of this study were to determine the effect of GH treatment (0.5–0.7 IU/kg/week) and the influence of some initial variables on adult height in patients with ISS. It was a non-randomized, observational study of 30 boys with ISS and a historical control group of 42 patients. The patients were followed until achieving their adult height. The mean height gain of the treated group attributable to GH was 4.5 cm. A stepwise regression model considering predicted adult height and target height as independent variables and final height as dependent variable gave an R2 coefficient of 0.38. We conclude that GH significantly increases final height in boys with ISS.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111W2gNF]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone and insulin-like growth factor-I care — diagnostic and outcome priorities emphasize improved diagnostics, including universal adoption of standardized IGF-I and GH assays and standards, refinement or development of GH provocative and IGF-I generation tests to better distinguish deficiency from sufficiency, and incorporation of expanding genetic testing and therapeutic responsiveness markers; imaging advances beyond current MRI for gross lesions may enable detection of subtle clinically relevant changes, while validated quality-of-life instruments and collection of long-term safety data in adults treated during childhood remain needed for defining effective, safe care.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^112DAxvd]. BMC Pediatrics (2025). Medium credibility.

Discussion

The most significant manifestation of children with idiopathic short stature is their height, which is significantly lower than that of their peers. The causes of this disorder are very complex and may involve complex interactions of genetic, endocrine, environmental and other factors. Children grow up slowly in height, often in lower positions in a class or group. Physically, a short stature may affect a child's physical function and motor ability. For example, when participating in some sports activities, they may face difficulties due to their insufficient height, which may affect their overall physical development. Psychologically, children with idiopathic short stature tend to have inferiority complex, anxiety, depression and other bad emotions. In school and social occasions, may suffer from other people's strange eyes and laugh at, do great harm to their mental health. This psychological pressure may even continue into adulthood, thus affecting their career choices and social life. In terms of bone age, most children have normal or slightly lagging bone age, which means that their bone maturity is relatively lagging compared with the actual age, but also provides a certain time window for potential therapeutic intervention. In terms of growth rate, children with idiopathic short stature usually grow at normal or slightly below normal rates. This kind of unobservable growth retardation is often easily ignored by parents, and it is not until the height gap with peers is gradually widened that attention is paid to it.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112SZmcK]. Hormone Research in Paediatrics (2016). Medium credibility.

Pediatric growth hormone deficiency (GHD) treatment — We recommend the use of GH to normalize AH and avoid extreme shortness in children and adolescents with GHD. (Strong recommendation, ●●●○) We suggest against routine cardiac testing, dual X-ray absorptiometry (DXA) scanning, and measurement of lipid profiles in children and adolescents treated with GH. (Conditional recommendation, ●○○○).

---

### Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review [^1114vhMR]. BMJ (2011). Excellent credibility.

Objective

To systematically determine the impact of growth hormone therapy on adult height of children with idiopathic short stature.

Design

Systematic review.

Data Sources

Cochrane Central Register of Controlled Trials, Medline, and the bibliographic references from retrieved articles of randomised and non-randomised controlled trials from 1985 to April 2010.

Data Extraction

Height in adulthood (standard deviation score) and overall gain in height (SD score) from baseline measurement in childhood.

Study Selection

Randomised and non-randomised controlled trials with height measurements for adults. Inclusion criteria were initial short stature (defined as height > 2 SD score below the mean), peak growth hormone responses > 10 μg/L, prepubertal stage, no previous growth hormone therapy, and no comorbid conditions that would impair growth. Adult height was considered achieved when growth rate was < 1.5 cm/year or bone age was 15 years in females and 16 years in males.

Results

Three randomised controlled trials (115 children) met the inclusion criteria. The adult height of the growth hormone treated children exceeded that of the controls by 0.65 SD score (about 4 cm). The mean height gain in treated children was 1.2 SD score compared with 0.34 SD score in untreated children. A slight difference of about 1.2 cm in adult height was observed between the two growth hormone dose regimens. In the seven non-randomised controlled trials the adult height of the growth hormone treated group exceeded that of the controls by 0.45 SD score (about 3 cm).

Conclusions

Growth hormone therapy in children with idiopathic short stature seems to be effective in partially reducing the deficit in height as adults, although the magnitude of effectiveness is on average less than that achieved in other conditions for which growth hormone is licensed. The individual response to therapy is highly variable, and additional studies are needed to identify the responders.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^112HuqpZ]. BMC Pediatrics (2025). Medium credibility.

The purpose of this meta-analysis was to identify the effects of short-acting GH supplementation on bone age and growth rate of children with idiopathic short stature through the collection and analysis of existing relevant studies, so as to provide a scientific basis for clinicians to formulate treatment plans, and also provide a reference for further research on the treatment of idiopathic short stature.

---

### American Association of Clinical Endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care [^115f1Kts]. Endocrine Practice (2019). High credibility.

Recombinant growth hormone (rGH) therapy goals and transition — In children, the primary goal is growth promotion to normalize final adult height, whereas for adults the main goal is to reverse adverse health consequences of hormone deficiency and improve quality of life; because goals differ, the transition to final adult height is an important juncture for re-assessment of GHD, continuation of rGH replacement in adulthood for those who remain GH-deficient, and planning long-term surveillance for those who are GH-sufficient.

---

### Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children [^114BbkXE]. The Journal of Clinical Endocrinology and Metabolism (2008). Low credibility.

Context

Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed.

Objective

The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender.

Design and Population

Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-to-treatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females).

Main Outcome Measure

For each category, mean pretreatment and mean ± 1 and ± 2 sd for the first-year HV on GH were assessed. Mean and mean ± 1 sd for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV.

Results

HV plots for each category as a factor of age at baseline are presented. Mean - 2 sd HV plots approximated the pretreatment HV.

Conclusion

Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 sd on these plots be considered a "poor" response. These curves may be used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.

---

### Recombinant growth hormone for idiopathic short stature in children and adolescents [^117ButHP]. The Cochrane Database of Systematic Reviews (2003). Low credibility.

Background

Idiopathic short stature (ISS) refers to children who are very short compared with their peers for unknown or hereditary reasons. Recombinant human growth hormone has been used to increase growth and final height in children with idiopathic short stature.

Objectives

To assess the effects of recombinant human growth hormone on short-term growth and final height in children with idiopathic short stature.

Search Strategy

Randomised controlled trials (RCTs) were sought by searching The Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, PubMed, Science Citation Index, BIOSIS and Current Controlled Trials (date of last search 10 December 2002). Article reference lists were assessed for trials and experts and pharmaceutical companies were contacted.

Selection Criteria

Randomised controlled trials were included if they were carried out in children with ISS with normal growth hormone secretion. Growth hormone (GH) had to be administered for a minimum of six months and be compared with placebo or no treatment. A growth or height outcome measure had to be assessed.

Data Collection and Analysis

Two reviewers assessed studies for inclusion criteria and for methodological quality. Data were extracted by one reviewer and checked by a second. The primary outcome was final height and secondary outcomes included short term growth, health related quality of life and adverse effects. To estimate summary treatment effects, data were pooled, when appropriate using a random effects model.

Main Results

Nine randomised controlled trials were included. One trial reported near final height in girls and found that girls treated with growth hormone were 7.5 cm taller than untreated controls (GH group, 155.3 cm ± 6.4; control, 147.8 cm ± 2.6; p = 0.003). The other trials reported short term outcomes. Results suggest that short-term height gains can range from none to approximately 0.7 SD over one year. One study reported health related quality of life and showed no significant improvement in growth hormone treated children compared with those in the control group. No serious adverse effects of treatment have been reported.

Reviewer's Conclusions

Results suggest that growth hormone therapy can increase short-term growth and improve (near) final height. Increases in height are such that treated individuals remain relatively short when compared with peers of normal stature. Further research in the form of large, multicentre RCTs are required. These should focus on final height, which is the best outcome for assessing the effects of growth hormone, and address quality of life and cost issues.

---

### Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial [^1139jmBV]. The Journal of Clinical Endocrinology and Metabolism (2004). Low credibility.

GH is often used to treat children with idiopathic short stature despite the lack of definitive, long-term studies of efficacy. We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children. Subjects (n = 68; 53 males and 15 females), 9–16 yr old, with marked, idiopathic short stature [height or predicted height ≤ -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult height. At study termination, adult height measurements were available for 33 patients after mean treatment duration of 4.4 yr. Adult height was greater in the GH-treated group (-1.81 ± 0.11 SDS, least squares mean ± sem) than in the placebo-treated group (-2.32 ± 0.17 SDS) by 0.51 SDS (3.7 cm; P < 0.02; 95% confidence interval, 0.10–0.92 SDS). A similar GH effect was demonstrated in terms of adult height SDS minus baseline height SDS and adult height SDS minus baseline predicted height SDS. Modified intent-to-treat analysis in 62 patients treated for at least 6 months indicated a similar GH effect on last observed height SDS (0.52 SDS; 3.8 cm; P < 0.001; 95% confidence interval, 0.22–0.82 SDS) and no important dropout bias. In conclusion, GH treatment increases adult height in peripubertal children with marked idiopathic short stature.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^111vp4N9]. BMC Pediatrics (2020). Medium credibility.

Discussion

This is the first observational multicenter study with FAH results in China on the efficacy of growth hormone alone for ISS. It was an observational study based on the clinical reality and reflected the real-world situation. In addition to the follow-up of FAH, the difference between FAH SDS and baseline height SDS and between FAH height SDS and TH SDS was also evaluated. It was found that a treatment course of 2 years or more had better efficacy. Even for over 10 years old ISS children, GH therapy could improve FAH if the treatment course was long enough.

Randomized controlled trials (RCTs) have been recognized as high-quality research evidence because of their rigorous grouping/screening criteria and standardized treatment. However, sometimes RCTs do not actually reflect the clinical reality because the efficacy of GH for ISS varies greatly and the GH treatment is highly individualized in the true clinical setting. Although real-world retrospective studies are feasible, their data are limited by the natural characteristics of the treated children. In the study of short stature, it is difficult to find a control group without treatment: in clinical practice, few children will adhere to the follow-up protocol if no GH treatment is applied. In the current study, patients who had received GH treatment for less than 3 months were included in the control group, which was based on the following consideration: although GH is effective for a patient, such efficacy within a short period (3 months) can be neglected for the FAH; thus, the result of a short treatment course of up to 3 months is similar to that of natural growth. Our data comprised real-world clinical data, which may be used as evidence for long-term treatment of GH for ISS.

---

### Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature [^116qSzTM]. The Journal of Clinical Endocrinology and Metabolism (2006). Low credibility.

Context

GH at 0.22 mg/kg.wk has been shown to have no effect on pubertal onset or pace, whereas GH at 0.5 mg/kg x wk has been shown to advance pubertal onset and bone maturation.

Objectives

Our objectives were to determine whether 0.37 mg/kg x wk GH advanced pubertal onset, pace, or bone maturation relative to 0.24 mg/kg x wk GH; whether 0.37 mg/kg x wk GH led to pubertal onset at an inappropriately early age; and whether age at start of GH therapy influenced pubertal onset.

Design

We conducted a randomized, open-label study to final height.

Patients

We studied children with idiopathic short stature.

Intervention

Patients were treated with 0.24 mg/kg x wk, 0.24 increasing to 0.37 mg/kg x wk, or 0.37 mg/kg x wk.

Main Outcome Measures

We assessed age at pubertal onset and rates of bone maturation, Tanner stage development, and increase in testicular volume (boys only).

Results

For the primary comparison between the 0.24 and 0.37 mg/kg x wk dose groups, median ages of pubertal onset (in years) were similar (13.7 vs. 13.5 for boys and 11.7 vs. 11.4 for girls) and were greater than those for the general population for each sex. Age at start of GH therapy did not appear to influence pubertal onset for either sex. Rates of pubertal pace and bone maturation were not significantly different between the 0.24 and 0.37 mg/kg x wk dose groups for either sex.

Conclusion

GH at 0.37 mg/kg x wk does not appear to accelerate pubertal onset, pace, or bone maturation compared with GH at 0.24 mg/kg x wk in patients with idiopathic short stature. From a clinical standpoint, our results suggest that the approved dose range of up to 0.37 mg/kg x wk GH does not lead to pubertal onset at an inappropriately early age.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^116EGTzR]. BMC Pediatrics (2020). Medium credibility.

Background

To evaluate the efficacy of GH in improving FAH in ISS children in a multicenter study.

Methods

A real-world observation was carried out. Children with ISS in seven hospitals in China were enrolled. The height gains standard deviation score and the height gain over the target height were evaluated.

Results

There were 344 ISS patients (217 boys and 127 girls). The baseline average age of boys and girls was 12.7 and 11.7 years, with bone age of 11.7 and 10.1 years, respectively. The baseline height SDS of boys and girls was − 3.07 and − 2.74, and the FAH SDS was − 1.91 and − 1.38, respectively. Compared with the baseline height SDS, the FAH SDS was significantly increased in both boys and girls (both P = 0.0000). The FAH SDS was the highest (gain by 1.54 SD) in the ≥ 2y treatment course group. Two hundred eighteen patients (218/344, 63.4%) had a FAH SDS > − 2 SD. Among these patients, girls in the 1–2y treatment course group and ≥ 2y group had a FAH SDS higher than TH SDS. Even in the control group, a spontaneous catch-up growth of 1.16 SD was observed. A multivariate linear regression model was used to analyze the results, with FAH SDS as the dependent variable. It was found that the treatment course and baseline height SDS in the boys' model were statistically significant (P < 0.05), whereas the baseline height SDS and baseline bone age significantly affected the girls' FAH SDS (P < 0.05).

Conclusions

Both girls and boys of ISS improved FAH by GH therapy even if treatments begin over 10 years old and majority of them reached TH. Some peri-puberty ISS will have a spontaneous height gain. We recommend the course of GH treatment more than 2 years for girls, and longer courses for boys.

---

### Treatment of children and adolescents with idiopathic short stature [^113YLKhG]. Nature Reviews: Endocrinology (2013). Medium credibility.

Idiopathic short stature (ISS) is defined as shortness in childhood without a specific cause. ISS may be familial or nonfamilial and may be associated with or without delay of pubertal development. Treatment can be considered in an attempt to reduce the psychological burden caused by short stature in childhood and adult life. If counselling alone is not sufficient, medical modifications of the growth process can be attempted. In cases with pubertal delay, sex steroids, such as testosterone and oxandrolone, can favourably influence height velocity and growth tempo, although adult height is not affected. Medications that prolong the process of growth — for example, gonadotropin-releasing hormone agonists or aromatase inhibitors — might increase adult height, but findings to date are still experimental. Growth hormone therapy is approved for the treatment of very short children with reduced adult height expectation, as evidence has accumulated that this therapy can increase height in childhood and in adult life. Sensitivity to growth hormone is impaired in patients with ISS; therefore, doses higher than a replacement dose have to be applied. This treatment still needs to be optimized in terms of efficacy, cost-effectiveness and long-term safety. A debate is ongoing concerning the psychological benefit of height increase, with clinicians warning against the medicalization of a deviation in height.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112GWGLN]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone and insulin-like growth factor-I treatment in children — guiding principles and evidence grading — The taskforce retrieved ~15,000 citations with approximately 6,300 specific to GHD or PIGFD, used a two-stage review with primary and secondary reviewers, and included all RCTs, with nonrandomized studies when they addressed the safety data. Evidence quality was judged as very low (●○○○), low (●●○○), moderate (●●●○), or high (●●●●), and recommendations were assessed as strong (denoted by "We recommend") or conditional (denoted by "We suggest"); consensus was defined as at least 6 of the 8 members agreeing on the recommendation as strong or weak. AH was selected as the primary outcome; in the absence of AH data, surrogate short-term outcomes such as growth velocity, change in height z-score, or change in predicted height were considered, but did not form the basis of a recommendation. For comparing AH across studies, GHD analyses used (AH SDS – midparental height [MPH] SDS) and, because MPH SDS formulas varied, the MPH SDS reported for each study was used; ISS analyses used (AH SDS minus baseline HtSDS), and (AH SDS – MPH SDS) was not used for ISS because MPH may not reflect genetic potential if one or both parents has an undiagnosed condition. Studies utilizing predicted AH were excluded. The taskforce emphasized harm prevention and described a conservative approach, recommending only practices with supporting evidence of sufficient quality that minimize potential risks to patients.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111dXr9W]. Hormone Research in Paediatrics (2016). Medium credibility.

Pediatric GHD diagnostic caveats — Technical Remark: A low GH concentration at the time of spontaneous hypoglycemia is alone insufficient to diagnose GHD. We recommend against reliance on GH provocative test results as the sole diagnostic criterion of GHD. (Strong recommendation, ●●●○).

---

### Final height gain by GH therapy in children with idiopathic short stature is dose dependent [^1124cNZG]. The Journal of Clinical Endocrinology and Metabolism (2002). Low credibility.

Recombinant human GH therapy to children with idiopathic short stature (ISS) increases growth velocity, but its effect on final height (FH) is still uncertain. The aim of this study was to investigate the effect of recombinant human GH on FH of patients with ISS who were treated according to two protocols in comparison to untreated historical controls. In study 1 (n = 24), all patients were treated with 14 IU (4.6 mg)/m(2) body surface x wk in the first year; thereafter the dosage was doubled if the growth response was insufficient. In study 2 (n = 34), patients were randomized into three arms: 18 IU (6 mg)/m(2) x wk; 27 IU (9 mg)/m(2) x wk; and 18 IU/m(2) x wk in the first year, followed by 27 IU/m(2) x wk thereafter. Observed or estimated FH was available for 53 patients. Thirty-four untreated controls from the same centers were available for comparison. Mean FH SD score in GH-treated children was -2.1, vs. -2.4 in controls (-2.4) (NS), but height SD score gain (1.3 vs. 0.7) and the difference between FH and predicted adult height (4.0 vs. 0.8 cm) were significantly greater. The growth response on an initial dosage of 27 IU/m(2) x wk (6.9 cm) was significantly better than on other regimens (2.8 cm). We conclude that a GH dosage of 27 IU (9 mg)/m(2) x wk to prepubertal children with ISS leads to a mean FH gain of approximately 7 cm, whereas regimens starting on lower dosages are less efficacious.

---

### Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the growth hormone research society, the lawson wilkins Pediatric Endocrine Society, and the European society for paediatric endocrinology workshop [^111Eu5hB]. The Journal of Clinical Endocrinology and Metabolism (2008). Low credibility.

Objective

Our objective was to summarize important advances in the management of children with idiopathic short stature (ISS).

Participants

Participants were 32 invited leaders in the field.

Evidence

Evidence was obtained by extensive literature review and from clinical experience.

Consensus

Participants reviewed discussion summaries, voted, and reached a majority decision on each document section.

Conclusions

ISS is defined auxologically by a height below -2 sd score (SDS) without findings of disease as evident by a complete evaluation by a pediatric endocrinologist including stimulated GH levels. Magnetic resonance imaging is not necessary in patients with ISS. ISS may be a risk factor for psychosocial problems, but true psychopathology is rare. In the United States and seven other countries, the regulatory authorities approved GH treatment (at doses up to 53 microg/kg.d) for children shorter than -2.25 SDS, whereas in other countries, lower cutoffs are proposed. Aromatase inhibition increases predicted adult height in males with ISS, but adult-height data are not available. Psychological counseling is worthwhile to consider instead of or as an adjunct to hormone treatment. The predicted height may be inaccurate and is not an absolute criterion for GH treatment decisions. The shorter the child, the more consideration should be given to GH. Successful first-year response to GH treatment includes an increase in height SDS of more than 0.3–0.5. The mean increase in adult height in children with ISS attributable to GH therapy (average duration of 4–7 yr) is 3.5–7.5 cm. Responses are highly variable. IGF-I levels may be helpful in assessing compliance and GH sensitivity; levels that are consistently elevated (> 2.5 SDS) should prompt consideration of GH dose reduction. GH therapy for children with ISS has a similar safety profile to other GH indications.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112hYZH3]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — growth hormone treatment approach: In the USA, for children who meet FDA criteria, we suggest a shared decision-making approach to pursuing GH treatment for a child with ISS, and the decision can be made on a case-by-case basis after assessment of physical and psychological burdens and discussion of risks and benefits. We recommend against the routine use of GH in every child with height SDS (HtSDS) ≤ −2.25. While studies have shown GH treatment increases the mean height of treated cohorts, there is marked interindividual variability in responses, including some individuals who do not respond to treatment.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111sN9oA]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone discontinuation and reassessment — pediatric growth hormone deficiency (GHD): Studies defining near–adult height (AH) used growth-rate thresholds ranging from 0.5 to 3 cm/ year, most commonly 2 to 2.5 cm/ year, and bone age cutoffs of 14–15 years in girls and 16–17 years in boys; the taskforce notes acromegalic changes are possible with pediatric dosing in adolescents with fused epiphyseal plates and should be avoided, and the panel recommends evaluation for persistent GHD. Given individual variability, it may be appropriate to discontinue growth hormone (GH) therapy earlier in some individuals, and in most clinics the diagnosis of GHD may be reconsidered with GH axis re-evaluation upon achievement of AH; re-examination of the GH axis 1 or more years after diagnosis of idiopathic IGHD in still growing children can yield normal results in a majority of patients, and nonrandomized data reported absolute height in centimeters not significantly different between groups that discontinued versus continued GH in specific contexts.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^113WAsHT]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone dose individualization after initiation in growth hormone deficiency: Interindividual variability in growth velocity suggests that subsequent dosing should be individualized, and one randomized study comparing standard weight-based versus individualized GH dosing modeled from pretreatment characteristics found that after 2 years of treatment the HtSDS – MPH SDS was similar between groups (−0.42 ± 0.46 vs. −0.48 ± 0.67) while the individualized group had a narrower SDS range (2.25 vs. 3.36). These models have not been evaluated by randomized controlled trials, and a statement on the most effective strategy to individualize GH dosing after GH initiation cannot be surmised from the available data.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^113oRCqX]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — growth hormone (GH) therapy is costly and of uncertain benefit, and GH for height augmentation in children who do not fit ISS criteria should be discouraged. The high cost of GH therapy is stated as USD 35,000–50,000 per year of treatment, and the text notes that no evidence exists that added height improves quality of life or provides any other benefit, with no justification to tolerate even small potential harms. It adds that treating patients with ISS requires careful evaluation and monitoring with consideration of alternative treatments such as psychological counseling, and concludes that regardless of parents' ability to pay, GH treatment for this purpose should be discouraged.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^112ja36o]. BMC Pediatrics (2025). Medium credibility.

Results

Search results

A total of 449 English articles were obtained through relevant database searches. Nine articles were finally included according to the inclusion and exclusion criteria. Literature retrieval flow chart was showed in Fig. 1.

Fig. 1
Document retrieval flow chart

Basic characteristics of included articles

Finally, nine articles were included, all of which were English language randomized controlled studies. A total of 491 patients were included, including 278 cases in the experimental group and 213 cases in the control group. Articles reported the growth rate as well as the bone age, while articles only reported the growth rate. The basic characteristics of the included articles are shown in Table 1.

Table 1
Basic characteristics of included articles

Quality of included literature

Of the nine included articles, eight were randomized controlled and assessed as "low risk"; 1 article was randomized and assessed as "high risk". In terms of the completeness of outcome data, no outcomes with incomplete data were found in the included articles, and all of them were rated as "low risk". All articles were used to identify other obvious sources of bias, and all were assessed as "unknown risk". See Fig. 2.

Fig. 2
Distribution diagram of quality bias of 9 articles

---

### Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone? [^115gZ4uS]. Journal of Pediatric Endocrinology & Metabolism (2012). Low credibility.

Aim

The aim of this study was to evaluate the effect of combined therapy with growth hormone (GH) and luteinizing hormone-releasing hormone agonist (LHRHa) on the near-final height (NFH) of children with idiopathic short stature (ISS) and growth hormone deficiency (GHD) in early puberty.

Methods

A retrospective analysis of 20 patients with ISS and 9 patients with GHD treated with combined therapy was undertaken. Twelve children with ISS and ten with GHD, treated with GH alone, served as controls. Patients were matched at baseline for chronological age, bone age, height standard deviation score (SDS), and pubertal development.

Results

Patients with ISS or GHD treated with combined therapy improved both their predicted adult height (PAH) at 2 years of therapy (ISS, p < 0.001; GHD, p = 0.03) and their NFH (ISS, p < 0.05; GHD, p = 0.05). Treatment with combined therapy did not generate additional benefits on the PAH after 2 years of therapy (ISS children, an increase of 7.9 ± 4.9 cm with combined therapy vs. 7.3 ± 6.0 cm with GH; GHD children, an increase of 6.8 ± 7.8 cm with combined therapy vs. 5 ± 5.9 cm with GH). The total height gain SDS was higher in patients treated with GH alone compared with those with combined therapy, but the difference was not significant (ISS children, a gain of 2.4 SDS with GH vs. 0.8 SDS with combined therapy; GHD children, a gain of 1.8 SDS with GH vs. 0.6 SDS with combined therapy).

Conclusions

Although 2 years of combined treatment with GH and LHRHa improved the PAH and the NFH of ISS and GHD patients in early puberty, this improvement was not significant compared with that observed in similar subjects treated with GH alone.

---

### Early growth hormone initiation leads to favorable long-term growth outcomes in children born small for gestational age [^112EM38c]. The Journal of Clinical Endocrinology and Metabolism (2023). Medium credibility.

Context

Early initiation of growth hormone (GH) therapy is recommended for short children born small for gestational age (SGA); however, real-world data indicate that treatment is often delayed.

Objective

We aimed to assess the impact of patient age at GH therapy initiation on long-term growth outcomes and safety in short children born SGA.

Methods

Analysis of pooled data from NordiNet® International Outcome Study (NCT00960128; 469 European clinics) and the ANSWER Program (NCT01009905; 207 US clinics), two large, complementary observational studies. Patients received GH as prescribed by their treating physician. Enrolled patients born SGA were categorized into three groups based on their age at GH treatment initiation: 2 to < 4 years, 4 to < 6 years, and ≥ 6 years. Patient characteristics at birth and GH initiation, auxology, and safety data were evaluated.

Results

The effectiveness analysis (treatment-naïve and prepubertal patients at GH initiation) included 3318 patients: 10.7% aged 2 to < 4 years at therapy initiation, 31.6% aged 4 to < 6 years, and 57.7% aged ≥ 6 years. Following 8 years of therapy, the mean improvement in height standard deviation score from baseline was significantly greater in the 2 to < 4 years group vs the 4 to < 6 years (+2.5 vs +2.2; P = 0.0054) and ≥ 6 years groups (+2.5 vs +1.7; P < 0.0001). No unexpected safety events were reported.

Conclusion

Early initiation of GH therapy in short children born SGA may be an important contributor to height optimization. The data are reassuring regarding the long-term safety of GH therapy in this population.

---

### Idiopathic short stature [^1166dsZH]. Journal of Pediatric Endocrinology & Metabolism (2001). Low credibility.

Idiopathic short stature (ISS) is a term used to describe the status of children with short stature that cannot be attributed to a specific cause. Many children diagnosed as having ISS have partial GH insensitivity, which can result from disturbances at various points of the GH-IGF-I axis. Several clinical studies on spontaneous growth in ISS showed that adult height was almost in the range of target height. GH treatment led to adult height not significantly higher than the pretreatment predicted adult height in most reports. No metabolic side effects have been observed, even when the dose was higher than in GH deficiency. Manipulation of puberty with gonadotrophin releasing hormone analogues reported by a few authors in a small number of children has shown conflicting results. Long-term psychological benefits of GH therapy for short normal children have not been demonstrated to date.

---

### Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency [^114eFrGD]. The Journal of Clinical Endocrinology and Metabolism (2008). Low credibility.

Context

The effect of GH therapy in short non-GH-deficient children, especially those with idiopathic short stature (ISS), has not been clearly established owing to the lack of controlled trials continuing until final height (FH).

Objective

The aim of the study was to investigate the effect on growth to FH of two GH doses given to short children, mainly with ISS, compared with untreated controls.

Design and Setting

A randomized, controlled, long-term multicenter trial was conducted in Sweden.

Intervention

Two doses of GH (Genotropin) were administered, 33 or 67 microg/kg.d; control subjects were untreated.

Subjects

A total of 177 subjects with short stature were enrolled. Of these, 151 were included in the intent to treat (AllITT) population, and 108 in the per protocol (AllPP) population. Analysis of ISS subjects included 126 children in the ITT (ISSITT) population and 68 subjects in the PP (ISSPP) population.

Main Outcome Measures

We measured FH sd score (SDS), difference in SDS to midparenteral height (diff MPHSDS), and gain in heightSDS.

Results

After 5.9 ± 1.1 yr on GH therapy, the FHSDS in the AllPP population treated with GH vs. controls was -1.5 ± 0.81 (33 microg/kg.d, -1.7 ± 0.70; and 67 microg/kg.d, -1.4 ± 0.86; P < 0.032), vs. -2.4 ± 0.85 (P < 0.001); the diff MPHSDS was -0.2 ± 1.0 vs. -1.0 ± 0.74 (P < 0.001); and the gain in heightSDS was 1.3 ± 0.78 vs. 0.2 ± 0.69 (P < 0.001). GH therapy was safe and had no impact on time to onset of puberty. A dose-response relationship identified after 1 yr remained to FH for all growth outcome variables in all four populations.

Conclusion

GH treatment significantly increased FH in ISS children in a dose-dependent manner, with a mean gain of 1.3 SDS (8 cm) and a broad range of response from no gain to 3 SDS compared to a mean gain of 0.2 SDS in the untreated controls.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^115BJaZG]. BMC Pediatrics (2020). Medium credibility.

Conclusions

In summary, both girls and boys of ISS improved FAH by GH therapy even if treatments begin over 10 years old and majority of them reached TH. Some peri-puberty ISS will have a spontaneous height gain. We recommend the course of GH treatment more than 2 years for girls, and longer courses for boys.

---

### Long-term response to GH therapy in short children with a delayed infancy-childhood transition (DICT) [^111QEcpW]. Pediatric Research (2011). Low credibility.

Transition of growth from infancy to childhood is associated with activation of the GH-IGF-I axis. Children with a delayed infancy-childhood transition (DICT) are short as adults. Thus, age at ICT may impact on growth response to GH. The objective was to investigate associations between growth response to GH treatment and ICT timing in children with idiopathic short stature (ISS) in a randomized, controlled, multicenter trial, TRN 88–080. A total of 147 prepubertal children (mean age, 11.5 ± 1.4 y) were randomized to receive GH 33 μg/kg/d (GH33, n = 43), GH 67 μg/kg/d (GH67, n = 61), or no treatment (n = 43). Data on growth to final height (FH) were analyzed after categorization into those with normal (n = 76) or delayed ICT (n = 71). Within the GH33 group, significant height gain at FH was only observed in children with a DICT (p < 0.001), with each month of delay corresponding to gain of 0.13 SD score (SDS). For the GH67 group, the timing of the onset of the ICT had no impact on growth response. In conclusion, ISS children with a DICT responded to standard GH dose (better responsiveness), whereas those with a normal ICT required higher doses to attain a significant height gain to FH.

---

### Motives for choosing growth-enhancing hormone treatment in adolescents with idiopathic short stature: a questionnaire and structured interview study [^113nsC3b]. BMC Pediatrics (2005). Low credibility.

Background

Growth-enhancing hormone treatment is considered a possible intervention in short but otherwise healthy adolescents. Although height gain is an obvious measure for evaluating hormone treatment, this may not be the ultimate goal for the person, but rather a means to reach other goals such as the amelioration of current height-related psychosocial problems or the enhancement of future prospects in life and society. The aim of our study was to clarify the motives of adolescents and their parents when choosing to participate in a growth-enhancing trial combining growth hormone and puberty-delaying hormone treatment.

Methods

Participants were early pubertal adolescents (25 girls, 13 boys) aged from 11 to 13 years (mean age 11.5 years) with a height standard deviation score (SDS) ranging from -1.03 to -3.43. All had been classified as idiopathic short stature or persistent short stature born small for the gestational age (intrauterine growth retardation) on the basis of a height SDS below -2, or had a height SDS between -1 and -2 and a predicted adult height SDS below -2. The adolescents and their parents completed questionnaires and a structured interview on the presence of height-related stressors, parental worries about their child's behavior and future prospects, problems in psychosocial functioning, and treatment expectations. Questionnaire scores were compared to norms of the general Dutch population.

Results

The adolescents reported normal psychosocial functioning and highly positive expectations of the treatment in terms of height gain, whereas the parents reported that their children encountered some behavioral problems (being anxious/depressed, and social and attention problems) and height-related stressors (being teased and juvenilized). About 40% of the parents were worried about their children's future prospects for finding a spouse or job. The motives of the adolescents and their parents exhibited rather different profiles. The most prevalent parental worries related to the current or future functioning of their children, while a few cases were characterized by no observed motives or by psychosocial problems only reported by the adolescents themselves.

Conclusion

The motives for participating in a growth-enhancing hormone trial are more obvious in the parents than in the adolescents themselves. Two out of three parents report worries about the future opportunities or observe modest current psychosocial problems in their children. The adolescents want to gain height, but the motivation underlying this remains unclear. Few of the adolescents experience psychosocial problems. Our analyses revealed differences among individuals in terms of motives, which implies that in an evaluation of hormone treatment, the importance of divergent outcome variables will also differ among individuals. Effectiveness evaluations of hormone treatment to increase height and the consequential fulfillment of other goals must be awaited.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^115rGqJg]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone therapy after malignancy — neoplasia counseling and timing: We recommend informing at-risk patients about available data on the potential risks of neoplasia, and we recommend shared decision-making that involves the patient, family, oncologist, and treating endocrinologist, including sharing with families the most recent risk data and the potential effect of GH treatment on timing of second neoplasm occurrence before GH initiation. For GH initiation after completion of tumor therapy with no evidence of ongoing tumor, a standard waiting period of 12 months to establish "successful therapy" of the primary lesion is reasonable but may be altered based on individual circumstances. A technical remark notes that although many intracranial tumors are not "malignant", they can recur, and there are no data to support different observation periods than for malignant tumors before initiating GH treatment.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111Tbzvn]. Hormone Research in Paediatrics (2016). Medium credibility.

Sequencing of GH and IGF-I therapy — We recommend a trial of GH therapy before initiating IGF-I therapy in patients with unexplained IGF-I deficiency, and patients with hormone signaling defects known to be unresponsive to GH treatment can start directly on IGF-I replacement; these include patients with very low or undetectable levels of GHBP and/or proven GH receptor (GHR) gene mutations known to be associated with Laron syndrome/GHIS, GH-neutralizing antibodies, STAT5b gene mutations, and IGF1 gene deletion or mutation.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^117QyeF7]. Hormone Research in Paediatrics (2016). Medium credibility.

Efficacy of growth hormone (GH) for growth hormone deficiency (GHD) — Recommendation 1.1 states: We recommend the use of GH to normalize adult height (AH) and avoid extreme shortness in children and adolescents with GHD. Evidence includes a French registry of 2,165 idiopathic IGHD patients showing mean height gain 1.1 ± 0.9 SDS and average AH −1.6 SD (girls 154 ± 5 cm; boys 165 ± 6 cm), with AH SDS 0.4 SD lower than mid-parental height (MPH) SDS on a GH dose of 0.14 mg/kg/week. Favorable predictors were younger age at GH start, greater bone age delay, prepubertal status, and severe GHD; in this cohort, 65% were prepubertal, 48% had peak GH secretion between 7 and 10 µg/L, sex steroid priming was used in only 2%, and MRI data were not reported. Compared with untreated idiopathic IGHD (mean AH SDS −4.7, range −3.9 to −6 SD), KIGS data showed treated outcomes: IGHD AH SDS −0.8 (males) and −1.0 (females); MPHD −0.7 (males) and −1.1 (females), with AH SDS − MPH SDS values of −0.2 (IGHD males), −0.5 (IGHD females), −0.4 (MPHD males), and −0.8 (MPHD females), and mean GH doses 0.21 mg/kg/week (IGHD) and 0.18 mg/kg/week (MPHD). (Strong recommendation, ●●●○)

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^116xBW9M]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone dosing for growth hormone deficiency — adult height outcomes and initiation dose: The body of evidence concerning the effect of different GH dosing regimens on AH is of moderate-to-low quality, reported mean GH doses were 0.18–0.24 mg/kg/week with a range between 0.11 and 0.28 mg/ kg/week, and multivariate analyses did not consistently reveal a correlation between higher dosing and greater AH. The guidelines taskforce endorses harm prevention over unproven benefits and notes higher long-term risk and a certain higher cost burden on health-care systems with high dosing. Therefore, the panel elected to recommend initiation of GH at the lower dose range, and the lowest dose with demonstrated efficacy should be used.

---

### A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation [^114KdyNV]. The Journal of Clinical Endocrinology and Metabolism (2001). Low credibility.

We assessed the effectiveness and safety of 3 yr combined GH and GnRH agonist (GnRHa) treatment in a randomized controlled study in children with idiopathic short stature (ISS) or intrauterine growth retardation (IUGR). Gonadal suppression, GH reserve, and adrenal development were assessed by hormone measurements in both treated children and controls during the study period. Thirty-six short children, 24 girls (16 ISS/8 IUGR) and 12 boys (8 ISS/4 IUGR), with a height SD score of -2 SD or less in early puberty (girls, B2–3; boys, G2–3), were randomly assigned to treatment (n = 18) with GH (genotropin 4 IU/m(2). day) and GnRHa (triptorelin, 3.75 mg/28 days) or no treatment (n = 18). At the start of the study mean (SD) age was 11.4 (0.56) or 12.2 (1.12) yr whereas bone age was 10.7 (0.87) or 10.9 (0.63) yrs in girls and boys, respectively. During 3 yr of study height SD score for chronological age did not change in both treated children and controls, whereas a decreased rate of bone maturation after treatment was observed [mean (SD) 0.55 (0.21) 'yr'/yr vs. 1.15 (0.37) 'yr'/yr in controls, P < 0.001, girls and boys together]. Height SD score for bone age and predicted adult height increased significantly after 3 yr of treatment; compared with controls the predicted adult height gain was 8.0 cm in girls and 10.4 cm in boys. Furthermore, the ratio between sitting height/height SD score decreased significantly in treated children, whereas body mass index was not influenced by treatment. Puberty was effectively arrested in the treated children, as was confirmed by physical examination and prepubertal testosterone and estradiol levels. GH-dependent hormones including serum insulin-like growth factor I and II, carboxy terminal propeptide of type I collagen, amino terminal propeptide of type III collagen, alkaline phosphatase, and osteocalcin were not different between treated children and controls during the study period. Thus, a GH dose of 4 IU/m(2) seems adequate for stabilization of the GH reserve and growth in these GnRHa-treated children. We conclude that 3 yr treatment with GnRHa was effective in suppressing pubertal development and skeletal maturation, whereas the addition of GH preserved growth velocity during treatment. This resulted in a considerable gain in predicted adult height, without demonstrable side effects. Final height results will provide the definite answer on the effectiveness of this combined treatment.

---

### Growth hormone therapy in children with idiopathic short stature… [^1126WkUw]. JAMA Network (2002). Excellent credibility.

We read with interest the meta-analysis of the effect of growth hormone therapy on height in children with idiopathic short stature1 but were surprised that 3 randomized controlled trials were not included in the review. We recently completed a review of the clinical and cost-effectiveness of GH in children, which was commissioned by the United Kingdom National Health Service Health Technology Assessment Programme on behalf of the National Institute for Clinical Excellence. 2 As part of this, we considered randomized controlled trials of GH in children with idiopathic short stature, GH deficiency, Turner syndrome, Prader-Willi syndrome, or chronic renal failure. Fourteen databases, including the Cochrane Library, MEDLINE, and the National Research Register, were searched. In addition, experts in the field were contacted. Bryant J, Cave C, Milne R.

Growth Hormone Therapy in Children With Idiopathic Short Stature. Arch Pediatr Adolesc Med. 2002; 156: 946–947.

---

### Recombinant growth hormone for idiopathic short stature in children and adolescents [^113qJhjJ]. The Cochrane Database of Systematic Reviews (2007). Low credibility.

Background

Idiopathic short stature (ISS) refers to children who are very short compared with their peers for unknown or hereditary reasons. Recombinant human growth hormone (GH) has been used to increase growth and final height in children with ISS.

Objectives

To assess the effects of recombinant human GH on short-term growth and final height in children with ISS.

Search Strategy

Studies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library, Science Citation Index, BIOSIS and Current Controlled Trials. Article reference lists were assessed for trials and experts and pharmaceutical companies were contacted.

Selection Criteria

Randomised controlled trials were included if they were carried out in children with ISS with normal GH secretion. GH had to be administered for a minimum of six months and be compared with placebo or no treatment. A growth or height outcome measure had to be assessed.

Data Collection and Analysis

Two reviewers assessed studies for inclusion criteria and for methodological quality. Data were extracted by one reviewer and checked by a second. The primary outcome was final height and secondary outcomes included short term growth, health related quality of life and adverse effects. To estimate summary treatment effects, data were pooled, when appropriate using a random effects model.

Main Results

Ten RCTs were included. One trial reported near final height in girls and found that girls treated with GH were 7.5 cm taller than untreated controls (GH group, 155.3 cm ± 6.4; control, 147.8 cm ± 2.6; P = 0.003); another trial which reported adult height standard deviation score found that children treated with GH were 3.7 cm taller than children in a placebo-treated group (95% confidence intervals 0.03 to 1.10; P < 0.04). The other trials reported short term outcomes. Results suggest that short-term height gains can range from none to approximately 0.7 SD over one year. One study reported health related quality of life and showed no significant improvement in GH treated children compared with those in the control group, whilst another found no significant evidence that GH treatment impacts psychological adaptation or self-perception in children with ISS. No serious adverse effects of treatment were reported.

Authors' Conclusions

GH therapy can increase short-term growth and improve (near) final height. Increases in height are such that treated individuals remain relatively short when compared with peers of normal stature. Large, multicentre RCTs are required which should focus on final height and address quality of life and cost issues.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^1153drF8]. Hormone Research in Paediatrics (2016). Medium credibility.

Initial GH dose in GHD — We recommend an initial GH dose of 0.16–0.24 mg/kg/week (22–35 μg/kg/day) with individualization of subsequent dosing. Technical Remark: Some patients may require higher doses.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112DtjxV]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) and primary IGF-I deficiency (PIGFD) thresholds — The height cutoff of −2.25 SD (1.2nd percentile) corresponds in adults to 160 cm (63 inches) for men and 150 cm (59 inches) for women [3]. The FDA approved IGF-I treatment in 2005 for the long-term treatment of growth failure in pediatric patients with severe PIGFD (defined as both height and serum IGF-1 concentration below − 3 SD despite normal or elevated GH levels) or with GH gene deletion who developed neutralizing antibodies to GH after a trial of GH therapy.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^114wPcKp]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone (GH) discontinuation threshold in pediatric dosing — duration of therapy — is stated as follows: We recommend that GH treatment at pediatric doses not continue beyond attainment of a growth velocity below 2–2.5 cm/year, and the decision to discontinue pediatric dosing prior to attainment of this growth velocity should be individualized.

---

### Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty [^116Gz7jo]. The Journal of Clinical Endocrinology and Metabolism (2007). Low credibility.

Objective

Our objective was to assess final height (FH) and adverse effects of combined GH and GnRH agonist (GnRHa) treatment in short adolescents born small for gestational age or with normal birth size (idiopathic short stature).

Design and Patients

Thirty-two adolescents with Tanner stage 2–3, age and bone age (BA) less than 12 yr for girls or less than 13 yr for boys, height sd score (SDS) less than -2.0 SDS or between -1.0 and -2.0 SDS plus a predicted adult height (PAH0) less than -2.0 SDS were randomly allocated to receive GH plus GnRHa (n = 17) or no treatment (n = 15) for 3 yr. FH was assessed at the age of 18 yr or older in girls or 19 yr or older in boys.

Results

FH was not different between treatment and control groups. Treated children had a larger height gain (FH-PAH0) than controls: 4.4 (4.9) and -0.5 (6.4) cm, respectively (P < 0.05). FH was higher than PAH0 in 76 and 60% of treated and control subjects, respectively. During follow-up, 50% of the predicted height gain at treatment withdrawal was lost, resulting in a mean gain of 4.9 cm (range, -4.0 to 12.3 cm) compared with controls. Treatment did not affect body mass index or hip bone mineral density. Mean lumbar spine bone mineral density and bone mineral apparent density tended to be lower in treated boys, albeit statistically not significant.

Conclusion

Given the expensive and intensive treatment regimen, its modest height gain results, and the possible adverse effect on peak bone mineralization in males, GH plus GnRHa cannot be considered routine treatment for children with idiopathic short stature or persistent short stature after being born small for gestational age.

---

### Initiation of growth hormone therapy in idiopathic short stature: do gender differences exist? [^1148gbEQ]. Journal of Pediatric Endocrinology & Metabolism (2015). Low credibility.

Background/Aims

Growth hormone (GH) registries indicate that boys receive preferential GH treatment for idiopathic short stature (ISS). The aim was to determine whether age, auxological parameters, pubertal status, and target height differ between genders at GH initiation.

Methods

Review of the computerized files of the endocrine department of a tertiary pediatric medical center identified 184 patients who started GH therapy for ISS between 2003–2011. Data on auxologic parameters, predicted height, parental height, and pubertal status were collected and compared between boys and girls.

Results

Boys accounted for a significantly higher percentage of the study group (65.8%, p < 0.001). At onset of GH therapy, there were no significant differences between boys and girls in age (10.2 ± 3.1 vs. 9.9 ± 2.4 years), height-standard deviation score (SDS) (-2.64 ± 0.5 vs. -2.79 ± 0.5), body mass index-SDS[(-0.65 ± 1.01) vs. (-0.80 ± 1.13)], or pubertal status (66% vs. 63.5% prepubertal). Predicted height-SDS was significantly higher in boys (-1.95 ± 1.05 vs. -2.56 ± 0.73, p < 0.001). Midparental height-SDS was similar in the two groups, as were paternal and maternal height.

Conclusions

The similar age, height deficit, and pubertal status at onset of GH treatment in boys and girls suggests that gender differences do not exist. Male predominance may stem from family preferences to treat boys. Future studies are warranted to assess the psychosocial aspects in the decision to initiate therapy.

---

### Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry [^111qZq2q]. BMJ (2002). Excellent credibility.

Objective

To evaluate the efficacy of recombinant growth hormone for increasing adult height in children treated for idiopathic isolated growth hormone deficiency.

Design

Observational follow up study.

Setting

Population based registry.

Participants

All 2852 French children diagnosed as having isolated idiopathic growth hormone deficiency whose treatment started between 1987 and 1992 and ended before 1996.

Main Outcome Measures

Change in height between the start of treatment and adulthood; classification of patients according to whether treatment was completed as scheduled or stopped early.

Results

Adult height was obtained for 2165 (76%) patients. The mean dose of growth hormone at start of treatment was 0.42 IU/kg/week. Height gain was 1.1 (SD 0.9) standard deviation (SD) scores, resulting in an adult height of -1.6 (0.9) SD score (girls, 154 (5) cm; boys, 167 (6) cm). Patients who completed the treatment gained 1.0 (0.7) SD score of height in 3.6 (1.4) years. Patients with treatments stopped early gained 0.6 (0.6) SD score in 2.7 (1.4) years while receiving treatment and a further 0.4 (0.9) SD score after the end of treatment. Most of the variation in height gain was explained by regression towards the mean, patients' characteristics, and delay in starting puberty. Severe growth hormone deficiency was associated with better outcome. Each year of treatment was associated with a gain of 0.2 SD score(1.3 cm).

Conclusion

The effect of growth hormone is unclear in many patients treated for so called idiopathic isolated growth hormone deficiency. Most of the patients have pubertal delay and a spontaneous growth potential, which must be taken into account when measuring the effect and cost effectiveness of treatments. Growth hormone deficiency should be clearly distinguished from pubertal delay, and criteria should restrict the definition to patients with severely and permanently altered growth hormone secretion as our results support the use of growth hormone in such patients. Long term trials are required for most patients currently treated.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^111iWLyX]. BMC Pediatrics (2020). Medium credibility.

As known, the efficacy of GH in the treatment of ISS remains controversial. In a variety of prospective/retrospective, randomized/non-randomized, and controlled/non-controlled trials, some researchers concluded that GH treatment improved ISS while others considered it ineffective. The efficacies in these studies varied dramatically. Some meta-analyses showed that GH-treated ISS patients might gain more FAH than untreated children, but were still shorter than the normal populations. In the meta-analysis performed by Deodati and Canfarani, three RCTs that followed the ISS patients until FAH were included, among which the average treatment course was 4.6–6.2 years. In these three RCTs the treated group gained 0.79 SDS (4.7 cm) more height than the control group without GH treatment. In the largest trial, the height attainment was 0.8 SDS (5 cm) more in the treatment group than in the control group. In the study by Sotos and Tokar, the height attainment was 1.9 SDS in the treatment group and only 0.49 SDS in the untreated control group. Wit et al. evaluated 239 children treated with GH, of whom only 50 were followed up until FAH. The FAH increased by 1.52–1.85 SDS compared with baseline height. In our current study, the FAH of boys and girls increased by 1.16 SD and 1.36 SD compared with baseline height, which is basically consistent with results reported in the literature. Compared with the 6 m-2y group, the ≥ 2y group had significantly more FAH gain over the baseline height. Therefore, GH treatment for more than 2 years can achieve better efficacy in ISS patients.

---

### Update in growth hormone therapy of children [^117JwZGR]. The Journal of Clinical Endocrinology and Metabolism (2011). Low credibility.

Although recombinant human GH (rhGH) has been available since 1985, there are several questions related to its use that remain unanswered. The Entrez-PubMed search engine was used to conduct a review of publications appearing since 2007 that address growth and GH treatment. Recent publications related to the diagnosis of GH deficiency, genetics of growth, the use of rhGH in different genetic conditions, in idiopathic short stature, and in puberty, and strategies to adjust rhGH dose were reviewed. New studies investigating the genetics of growth and the response to rhGH therapy in different groups are helping in the understanding of the physiology of normal growth. Although in most children treated with rhGH there is a short-term benefit, the clinical relevance of the benefits after long-term treatment in some conditions remains unclear. The challenges are to define milder forms of GH deficiency and to assess the relevance of the benefits, if any, caused by rhGH in different patient populations and the best therapeutic approach for these patients. Well-designed long-term studies using anthropometric, genetic, and laboratory data that will also assess long-term quality of life benefits are needed to help clinicians select patients to initiate treatment with rhGH and to adjust treatment to improve outcome.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^1123Kq9r]. Hormone Research in Paediatrics (2016). Medium credibility.

Pediatric Endocrine Society guideline on growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment — scope, population, and methods — states that on behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, the guideline updates the guidelines published in 2003 on the use of GH and focuses on idiopathic short stature (ISS), GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. The guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation) and provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient, and notes that in many instances careful review highlights areas that need further research.

---

### Short stature and growth hormone therapy… [^114yQ7Wq]. JAMA Network (1996). Excellent credibility.

Objective. — To determine current expert opinion and recommendations regarding the controversial issue of the use of growth hormone to treat short children who do not have classical GH deficiency. Study Design. — Analysis of a national survey mailed to 534 US physician experts on the management of short stature with a response rate of 81. 3%. Main Outcome Measure. — The experts' GH treatment recommendations. Results. — The physicians reported that approximately 58% of their current patients undergoing GH therapy have classical GH deficiency, while 42% have other conditions. The proportion of physicians who recommended GH treatment of short non-GHD children ranged from 1% to 74% over all case scenarios presented.

The likelihood of GH being recommended depended on the physiological growth characteristics of the child, contingency factors, and physician beliefs. Each of these factors exerted highly significant, independent, and additive effects on decisions to recommend GH. Conclusion. — Our results indicate that many pediatric endocrinologists consider GH treatment appropriate for selected short non-GHD children, going beyond current Food and Drug Administration-approved indications for GH. Decisions to recommend GH for a non-GHD child rest on a combination of medical, social, and perceptual factors; variations in treatment patterns stem from variations in these influences.

Future GH use will likely be determined not only by the results of controlled trials, but also by family preferences, producer pricing, and physician perceptions of the value of height and GH therapy. Cuttler L, Silvers JB, Singh J, et al. Short Stature and Growth Hormone Therapy: A National Study of Physician Recommendation Patterns. JAMA. 1996; 276: 531–537.

---

### Idiopathic short stature… [^115K9DHN]. JAMA Network (2025). Excellent credibility.

Importance Approximately 2% of children are defined as having short stature. Deciding when to pursue recombinant human growth hormone therapy to increase adult height is controversial. Objective To review the management of children with idiopathic short stature, including diagnostic evaluation and therapeutic options. Evidence Review Systematic literature search of PubMed, Embase, and the Cochrane Library databases. For height outcome, articles were limited to studies reporting adult height and to systematic reviews. Findings Recombinant human growth hormone therapy of children with idiopathic short stature increases height in some children. The estimated mean gain in adult height is 5. 2 cm. The cost-benefit ratio is controversial. Treatment with growth hormone appears safe in the short term, while data on long-term effects are limited because studies of long-term efficacy were not powered to determine safety.

Conclusions and Relevance Growth hormone treatment may be considered in some children with idiopathic short stature. Cohen LE. Idiopathic Short Stature: A Clinical Review. JAMA. 2014; 311: 1787–1796. doi: 10.1001/jama.2014.3970 © 2024 Artificial Intelligence Resource Center Customize your JAMA Network experience by selecting one or more topics from the list below.

---

### Child with suspected short stature [^1164WAx6]. PES (2020). High credibility.

Differential diagnosis of short stature — common causes and idiopathic short stature criteria are specified as follows: Common causes include familial or intrinsic short stature, constitutional delay of growth and puberty, idiopathic short stature, and small for gestational age without catch up growth by 2 years. In constitutional delay, children typically cross percentiles downwards in the first 3 years and then grow at a normal growth velocity on the lower percentiles or just below the 3rd percentile, and bone age is delayed. Idiopathic short stature is defined as height < 2.25 SD below the mean for age and sex (shortest 1.2% of children) – FDA definition, with notes that patients are unlikely to attain adult height in the normal range (less than 63 inches for boys and 59 inches for girls) and that diagnostic evaluation excludes other causes of short stature.

---

### Can growth hormone stimulation tests in children predict the response to growth hormone treatment? [^11554KXw]. Endocrine Practice (2025). Medium credibility.

Objective

The efficacy of growth hormone (GH) treatment in short, healthy children diagnosed with growth hormone deficiency (GHD) or idiopathic short stature (ISS) suggests an overlap between these 2 conditions. Although imperfect and inconsistent, GH stimulation testing (GHST) remains the primary diagnostic tool for differentiating GHD and ISS, influencing GH treatment eligibility and dosing. This study aims to assess the clinical significance of GHST by comparing the response to GH treatment in children diagnosed with GHD or ISS based on their GHST results.

Methods

A retrospective study in an endocrine clinic at a tertiary pediatric referral center comparing the response to GH treatment over 3 years in children diagnosed with GHD or ISS.

Results

Two hundred ninty-one children treated with GH, 97 children diagnosed with GHD, and 194 with ISS are included in the analysis. Height significantly improved, and insulin-like growth factor-1 levels increased independent of the GHST results, gender, or pubertal status (P < .001). When adjusting for dosage, height gain was not associated with the treatment indication, GHD or ISS, or GHST peak levels.

Conclusions

Our findings indicate similar responses to GH treatment in children classified as GHD or ISS based on GHST. These results suggest that the pivotal role of GHST in diagnosing and treating short children should be reconsidered.

---

### Motives for choosing growth-enhancing hormone treatment in adolescents with idiopathic short stature: a questionnaire and structured interview study [^1173YVjd]. BMC Pediatrics (2005). Low credibility.

Conclusion

Our study demonstrates that the motives of parents to let their children participate in a growth-enhancing hormone trial are more obvious than the motives of the early pubertal adolescents themselves. Two out of three parents reported worries about the future opportunities or observed modest current psychosocial problems in their children. The adolescents wanted to gain height, but the underlying motivation remains unclear. Few of the adolescents experienced psychosocial problems. Our analyses showed that motives varied among individuals. This result implies that when evaluating hormone treatment, the importance of divergent outcome variables will also differ among individuals. Effectiveness evaluations of hormone treatment to increase height and the consequential fulfillment of other goals must be awaited.

---

### Near adult heights after growth hormone treatment in patients with idiopathic short stature or idiopathic growth hormone deficiency [^115RSgjD]. Journal of Pediatric Endocrinology & Metabolism (2003). Low credibility.

Objective

Determination of near adult height (NAH) after recombinant human growth hormone (rhGH) therapy in patients with idiopathic short stature (ISS, maximum stimulated growth hormone [MSGH] > 10 ng/ml) or idiopathic growth hormone deficiency (IGHD, MSGH ≤ 10 ng/ml) enrolled in the National Cooperative Growth Study Substudy 2.

Methods

Female NAH was defined as height at age 18 or age 14 plus Tanner stage 4; male NAH was defined as height at age 20 or age 16 plus Tanner stage 4 or 5.

Results

Both groups had similar enrollment heights: IGHD -2.7 ± 0.7 versus ISS -2.8 ± 0.6 (mean height standard deviation score [SDS] ± SD). After rhGH treatment, there were no significant differences in NAH between the IGHD and ISS groups (-1.4 ± 1.0 versus -1.6 ± 1.0). Enrollment height SDS and MSGH value were significant predictors of delta height for the children with IGHD but not for the children with ISS (R2 = 0.45 IGHD versus R2 = 0.22 ISS).

Conclusion

We conclude that MSGH values should not be used as the primary criterion for rhGH therapy.

---

### Early growth hormone initiation leads to favorable long-term growth outcomes in children born small for gestational age [^112pzXa3]. The Journal of Clinical Endocrinology and Metabolism (2023). Medium credibility.

Conclusions

This analysis suggests early initiation of GH therapy in short children born SGA may improve height optimization. The safety data are reassuring regarding the long-term safety of GH therapy in this population.

---

### Prevention of growth deceleration after withdrawal of growth hormone therapy in idiopathic short stature [^1165KUnn]. The Journal of Clinical Endocrinology and Metabolism (2002). Low credibility.

The treatment of children with idiopathic short stature by daily injections of human GH (hGH) is followed after its withdrawal by a growth deceleration with normal serum GH and IGF-I levels. The present study was designed to understand and prevent growth deceleration. We hypothesized that this phenomenon is due to tolerance at the target organ level, that tolerance develops in response to the unphysiological pharmacokinetics of daily-injected hGH, and that alternate day hGH therapy will prevent it. Thirty-eight prepubertal children with idiopathic short stature, aged 3.3–9.0 yr, were studied. Their heights were less than -2 SD score, growth rate was above the 10th percentile for age, bone age was less than 75% of chronological age, and the stimulated serum GH concentration was greater than 10 microg/liter. The children were matched for sex, height, and growth velocity SD score to receive daily or alternate day hGH at the same weekly dose of 6 mg/m(2) for a period of 2 yr. The 1st and 2nd year mean growth velocities were 3.4 and 2.3 SD score for the daily therapy group and 3.0 and 2.0 SD score for the alternate day group, respectively (P = NS). Over the initial 6 months after withdrawal of therapy, and growth velocity decelerated to a nadir of -3.9 SD score in the daily therapy group, whereas it decelerated in the alternate day group to only -0.2 SD score (P < 0.01). Over the entire 2 yr off therapy the latter group maintained mean growth rates of -0.2 to -1.2 SD score, similar to their pretreatment velocities. The daily group recovered slowly to resume their mean pretreatment rate only on the fourth semiannual evaluation off therapy. The cumulative 4-yr growth velocity (2 yr on and 2 yr off therapy) of the alternate day group was greater than that of the daily therapy group (mean, 0.9 vs. 0.3 SD score; P < 0.002). At the end of the 4-yr therapy period, the adult height prediction of the alternate day group was greater than that of the daily group by a mean 6.5 cm (P = 0.06). It is concluded that growth deceleration after withdrawal of hGH therapy in idiopathic short stature is due to tolerance to GH and IGF-I in response to the unphysiological pharmacokinetics of daily-injected hGH and that alternate day therapy allows for an alternate day physiological GH profile, thus preventing tolerance during therapy and growth deceleration thereafter.

---

### Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect [^114FbLEU]. The Journal of Pediatrics (2005). Low credibility.

Objectives

To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2).

Study Design

Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24→0.37), or 0.37 mg/kg/week. Final height was evaluated in 50 patients at study completion (mean treatment duration, 6.5 years).

Results

Patients who received 0.37 mg/kg/week (n = 72) experienced a significantly greater increase in height velocity than those who received 0.24 mg/kg/week (n = 70) (treatment difference = 0.8 cm/year; p = 0.003) or 0.24→0.37 mg/kg/week (n = 67) (treatment difference = 0.9 cm/year; p = 0.001). For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups. For the primary comparison between the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, the mean treatment difference (adjusted for differences in baseline predicted height SDS) was 0.57 SDS (3.6 cm; p = 0.025). Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters. Final height measurements were within the normal adult height range for 94% of patients randomized to 0.37 mg/kg/week who continued to final height.

Conclusion

GH treatment dose-dependently increases height velocity and final height in children with idiopathic short stature.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^116QLpQP]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — GH counseling, monitoring, and dosing state that patients and their parents/guardians should be counseled that not starting GH therapy at all is an option, and since not all children with ISS will respond to GH therapy, HtSDS improvement after 12 months of therapy should be assessed and the discontinuation of GH therapy should be considered if adequate height gain has not been achieved; patients should be monitored for changes in psychological functioning and quality of life. Because there is overlap in response between dosing groups, we suggest initiating GH at a dose of 0.24 mg/ kg/week, with some patients requiring up to 0.47 mg/kg/ week; given the unresolved long-term risks of treatment, there should be caution in using higher doses, and GH therapy should be discontinued in patients who do not respond.

---

### Motives for choosing growth-enhancing hormone treatment in adolescents with idiopathic short stature: a questionnaire and structured interview study [^116yh6Xr]. BMC Pediatrics (2005). Low credibility.

Background

Growth-enhancing hormone treatment is considered a possible intervention in short but otherwise healthy adolescents. Although height gain is an obvious measure for evaluating hormone treatment, this may not be the ultimate goal of the person, but rather a means to reach other goals such as to ameliorate current height-related psychosocial problems or to enhance future prospects in life and society.

Psychosocial functioning has been emphasized in considerations of the motives of children with idiopathic short stature (ISS) and their parents seeking hormone treatment to achieve a height gain. Children who have never been medically referred do not seem to suffer from their stature. Most studies involving medically referred children have revealed reduced social competence, while internalizing and externalizing behavior, body image, self-esteem, and scholastic competence have been shown, on average, to be between normal and below normal. In addition to the possibility of improving psychosocial functioning, several other factors are hypothesized to motivate children and their parents to choose hormone treatment, including the experience of height-related psychosocial stressors (such as being teased or juvenilized), future expectations for finding a spouse and a desired career commensurate with intellectual potential and interests, and the expectation of a treatment-induced height gain.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^113j3Ng2]. Hormone Research in Paediatrics (2016). Medium credibility.

Insulin-like growth factor-I (IGF-I) monitoring during growth hormone therapy: We suggest measurement of serum IGF-I levels as a tool to monitor adherence and IGF-I production in response to GH dose changes.

---

### Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature [^11519kE7]. The Journal of Clinical Endocrinology and Metabolism (2016). Low credibility.

Context

Growth of short children in puberty is limited by the effect of estrogen on epiphyseal fusion.

Objectives

To compare: 1) the efficacy and safety of aromatase inhibitors (AIs) vs GH vs AI/GH on increasing adult height potential in pubertal boys with severe idiopathic short stature (ISS); and 2) differences in body composition among groups.

Design

Randomized three-arm open-label comparator.

Setting

Outpatient clinical research.

Patients

Seventy-six pubertal boys [mean (SE) age, 14.1 (0.1) years] with ISS [height SD score (SDS), -2.3 (0.0)].

Intervention

Daily AIs (anastrozole or letrozole), GH, or AI/GH for 24–36 months.

Outcomes

Anthropometry, bone ages, dual x-ray absorptiometry, spine x-rays, hormones, safety labs.

Results

Height gain [mean (SE)] at 24 months was: AI, +14.0 (0.8) cm; GH, +17.1 (0.9) cm; AI/GH, +18.9 (0.8) cm (P < .0006, analysis of covariance). Height SDS was: AI, -1.73 (0.12); GH, -1.43 (0.14); AI/GH, -1.25 (0.12) (P < .0012). Those treated through 36 months grew more. Regardless of treatment duration, height SDS at near-final height [n = 71; age, 17.4 (0.2) years; bone age, 15.3 (0.1) years; height achieved, ∼97.6%] was: AI, -1.4 (0.1); GH, -1.4 (0.2); AI/GH, -1.0 (0.1) (P = 0.06). Absolute height change was: AI, +18.2 (1.6) cm; GH, +20.6 (1.5) cm; AI/GH, +22.5 (1.4) cm (P = 0.01) (expected height gain at -2.0 height SDS, +13.0 cm). AI/GH had higher fat free mass accrual. Measures of bone health, safety labs, and adverse events were similar in all groups. Letrozole caused higher T and lower estradiol than anastrozole.

Conclusions

Combination therapy with AI/GH increases height potential in pubertal boys with ISS more than GH and AI alone treated for 24–36 months with a strong safety profile.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^112uHoTw]. BMC Pediatrics (2025). Medium credibility.

Introduction

Idiopathic short stature (ISS) is a common condition in pediatrics and one of the growth and development disorders. The main manifestation of ISS is that the height of children is significantly lower than the average height of children of the same age and gender who are normal. The body proportion is normal, and there is no definite etiology such as systemic, endocrine and nutritional diseases or chromosome abnormalities. During growth, children grow at a slower rate, which may affect their future height potential and mental health. At present, one of the main treatment methods for ISS is growth hormone (GH) therapy, but the therapeutic effect varies from individual to individual. GH is a peptide hormone secreted by the anterior pituitary gland of human body, which can promote the synthesis of protein, cell proliferation and bone growth. Under the long-term action of GH, the growth and development process of the human body can be significantly affected. In the treatment of some diseases such as GH deficiency, Turner syndrome and Prader-Willi syndrome, long-term or even lifetime use of GH may be required to maintain normal growth, development and body metabolic function. However, long-term use of GH has certain effects, such as abnormal glucose metabolism, slipped capital femoral epiphysis, idiopathic intracranial hypertension, etc. The treatment of ISS mainly focuses on promoting faster growth and improving the symptoms related to specific growth disorders in the short term. It is suitable for the use of short-acting GH replacement therapy, which can play a role in promoting rapid growth after injection. At the same time, unnecessary risks are reduced because treatment options can be adjusted timely according to the specific conditions of children. However, the effect of short-acting GH supplementation on bone age and growth rate in children with idiopathic short stature is still controversial. Although studies have explored the effects of short-acting GH supplementation on children with idiopathic short stature, the results of these studies are inconsistent. In addition, the existing studies are mostly single, with small sample size and lack of systematic comprehensive analysis. Therefore, it is necessary to conduct a meta-analysis to comprehensively evaluate the effects of short-acting GH supplementation on bone age and growth rate of children with idiopathic short stature, so as to provide more reliable evidence for clinical treatment.

---

### Construction and evaluation of a height prediction model for children with growth disorders treated with recombinant human growth hormone [^113Nuymw]. BMC Endocrine Disorders (2025). Medium credibility.

Introduction

Recombinant human growth hormone (rhGH) was initially approved in 1985 for the treatment of children with growth hormone deficiency (GHD). Since then, it has received approval for various other pediatric conditions linked to growth disorders, including idiopathic short stature, Turner syndrome, being small for gestational age, chronic renal insufficiency, Prader-Willi syndrome, Noonan syndrome, and SHOX gene defects. In children with GHD, rhGH therapy has become a standard treatment, widely used to promote height gain and improve quality of life.

Despite the proven efficacy of rhGH therapy, there is considerable variability in treatment response among patients. Multiple factors influence the outcome, including age, sex, bone age, baseline height, and growth hormone levels. The complex interactions among these factors make it challenging for clinicians to predict individual responses to rhGH therapy, particularly during the early stages of treatment. Therefore, there is an urgent need for an accurate and practical predictive model to assess short-term response to rhGH therapy, aiding optimised treatment decisions and avoiding unnecessary long-term treatment.

In recent years, machine learning methods have gained significant attention in medical research due to their ability to handle complex, multidimensional data. Compared to traditional statistical methods, machine learning can identify nonlinear relationships in high-dimensional data and offers strong predictive and generalisation capabilities. This potential makes machine learning an attractive approach for constructing predictive models in medicine.

In this context, we aim to develop and validate a predictive model using machine learning to evaluate the short-term height response in children with growth disorders undergoing rhGH therapy. Our goal is to create a user-friendly and accurate model that helps clinicians predict individual treatment outcomes early, facilitating personalized therapy. To achieve this, we analysed extensive clinical data from a large cohort of paediatric patients. We also assessed the accuracy and robustness of the model, and further explored the clinical significance of key predictive factors within the model.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^114AUrYc]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — growth hormone dosing and response benchmarks are described as follows: A controlled series found no difference in AH using 0.5 or 1 IU/kg/week (roughly equivalent to 0.17 or 0.33 mg/kg/week), and no data exist to support advantages of weight-based dosing at > 0.47 mg/kg/week in children with ISS. Short-term data suggest that targeting GH dosing to IGF-I levels may improve the growth response, but there are no data to AH. Modeling suggests determinants may include height deficit relative to genetic targets (HtSDS – MPH SDS) and younger age at treatment start (< 10 years in boys and < 9 years in girls). For benchmarking response, at ages 3–8 years healthy children may have a normal increase in HtSDS of < 0.3, and many studies use an increase in HtSDS of greater than 0.3–0.5 over 1 year; these values have been suggested in a consensus statement, and published height velocity targets for the first year of GH therapy can be used as reference.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^115vvgm1]. BMC Pediatrics (2025). Medium credibility.

Conclusion

In summary, the results of this meta-analysis showed that short-acting GH supplementation significantly increased growth rate and had little effect on bone age in children with idiopathic short stature.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112ZuYZf]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone dosing frequency — Daily dosing of GH resulted in higher absolute height gain and gain in HtSDS than dividing the same weekly dose as thrice weekly (TIW) in 1–4 years of comparison study; in the studies reporting AH in GH-treated children, dosing of GH was 6–7 days per week in the majority of studies, and TIW dosing is not suggested.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^115UD1Z8]. Hormone Research in Paediatrics (2016). Medium credibility.

IGF-I dosing — suggested regimens and evidence: We suggest an IGF-I dose of 80–120 μg/kg, b.i.d., noting that similar short-term outcomes were seen with 80 and 120 μg and there is no strong evidence supporting superiority of one dose over the other (Conditional recommendation); Technical Remark: Outside of the USA, IGF-I is also used at 150–180 μg/kg q.d. Reported regimens include twice-daily 40–120 μg/kg/dose or once-daily 150–200 μg/kg, and the once-daily approach is still followed by some, claiming similar growth velocities and fewer side effects. Evidence is limited to heterogeneous, largely short-term data; for example, a single open-label, uncontrolled report of adult or near-AH (defined as bone age at least 16 years for males and 14 for females) in 21 patients treated with IGF-I for a mean of 10 years began at 40 μg/kg b.i.d. and increased by 40 μg/kg increments every 2 weeks up to 120 μg/kg b.i.d., with some receiving 40–80 μg/kg b.i.d. and some as high as 150 μg/kg b.i.d., and was further confounded by gonadotropin-releasing hormone agonist therapy in 9 subjects; overall, this approach is fraught with limitations that preclude determination of definitive recommendations.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^114TAbYU]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — adult height outcomes with growth hormone (GH) show across randomized controlled trials (RCTs) using GH dose ranges of 0.22–0.47 mg/kg/week, injections 3–7 per week, and treatment durations 4.6–6.2 years that combining the 3 RCTs including 237 subjects (152 treated, 85 controls) with 146 followed to near adult height (AH) or AH (100 treated, 46 controls) the mean height gain of GH-treated children exceeded controls by 0.79 SDS (95% CI 0.50–1.09) or 4.7 cm (1.85 inch). A meta-analysis suggested approximately 4–6 cm AH gain (range 2.3–8.7 cm), averaging about 1 cm per year of treatment, and a retrospective study reported HtSDS gain of +1.9 (± 0.76) in GH-treated ISS at 0.32 ± 0.03 mg/kg/week versus +0.49 SDS in untreated for a net gain of 1.41 SDS.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111nMrUL]. Hormone Research in Paediatrics (2016). Medium credibility.

Primary insulin-like growth factor-I deficiency (PIGFD) — treatment and diagnostic approach are outlined: We recommend the use of IGF-I therapy to increase height in patients with severe PIGFD (Strong recommendation, ●●●○). Laron syndrome/growth hormone insensitivity syndrome (GHIS) is the most common and prototypical PIGFD condition; untreated heights are −4 to −10 SD in childhood with AHs of 106–142 cm in males and 95–136 cm in females. In treated PIGFD cohorts followed for a mean duration of 10 years to adult or near-AH (defined as bone age at least 16 years for males and 14 for females), mean growth velocity increased from 3.1 cm/year pretreatment to 7.4 cm/year in year 1, 5.6 cm/year in year 2, and 3.9–5 cm/year in years 3–12, with HtSDS increasing by a mean of +1.9 SD and (near) AH a mean of 13.4 cm more than expected. For diagnosis, we suggest a four-stage approach (Conditional recommendation, ●●○○): screening with auxological parameters and low IGF-I concentration; exclusion of secondary causes including under-nutrition, hepatic disease, and GHD; assessing GHBP where very low or undetectable levels suggest Laron syndrome/GHIS while normal levels are noninformative; and noting that IGF-I generation test and mutation analyses can be helpful, but have limitations.

---

### Growth hormone treatment in children with short stature: impact of the diagnosis on parents [^115QgYRb]. Journal of Pediatric Endocrinology & Metabolism (2024). Medium credibility.

Objectives

This prospective multicenter study aimed (1) to examine changes in parent-reported health-related quality of life (HRQOL) of children with short stature and the effects of the children's condition on parents themselves within the first year of human growth hormone (hGH) treatment and (2) to predict effects on parents based on main and interaction effects of children's HRQOL and increase in height.

Methods

A total of 110 parents of children aged 4–18 years, diagnosed with idiopathic growth hormone deficiency, small for gestational age, or idiopathic short stature, were recruited from 11 participating German pediatric endocrinologists and asked to fill out the short stature-specific Quality of Life in Short Stature Youth (QoLISSY) Questionnaire before hGH treatment was initiated and one year later.

Results

Negative effects of the children's short stature on the parents decrease over time, independent of diagnosis and treatment status. Furthermore, treatment status and height increase moderated the links between children's improved HRQOL as perceived by their parents and decreased caregiving burden.

Conclusions

Based on the children's improved HRQOL and the parent's decrease in caregiving burden, patient-reported outcomes that consider parental and child's perspectives should be considered when deciding on hGH treatment for children.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^114cyATr]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone (GH) treatment — balance of benefit, risk, and cost in growth hormone deficiency (GHD) versus idiopathic short stature (ISS): Children with severe GHD clearly benefit from GH treatment such that benefits markedly outweigh potential harms, whereas for children with ISS who do not have GHD the benefits of achieving taller stature via GH are uncertain and of lesser magnitude; the degree of psychosocial disability in ISS is not clear, and accordingly when benefits are limited and uncertain, even small or low-probability harms become important because children with ISS are healthy and will remain healthy without treatment.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^114jTd16]. BMC Pediatrics (2020). Medium credibility.

Background

Idiopathic short status (ISS) is defined as a condition in which the height of an individual is more than 2SD score (SDS) below the corresponding mean height for a given age, sex, and population group without evidence of systemic, endocrine, nutritional, or chromosomal abnormalities. Children with ISS have normal birth weight and are GH sufficient. The incidence of ISS (including constitutional delay of growth and puberty and familial short stature) is about 23 in 1000. In 2003, the US Food and Drug Administration approved growth hormone (GH) for the treatment of ISS patients (height < − 2.25 SD). The main purpose of GH therapy for ISS is to attain normal adult height and avoid daily life inconvenience and psychological problems caused by extreme or unacceptable short stature. However, few clinical studies have explored whether the final adult height (FAH) can reach the normal range after GH therapy. FAH is considered the golden indicator for evaluating the efficacy of GH therapy. However, the predicted FAH following a short period of treatment is dynamic and cannot reflect the actual FAH. Owing to the heterogeneity of the treated ISS populations and the individualization of treatment, only a few randomized trials with small sample sizes have observed ISS until FAH. A randomized study of FAH typically takes 8 years or more to complete and is often difficult to implement in clinical settings. Thus, most of the currently available studies only have small samples and are carried out in a single center. More studies are needed to confirm the efficacy of GH in the treatment of ISS.

In the clinical real world, many ISS children's parents are willing to observe their children growth when they are young. As children grow older and become peri-puberty, more people come to see doctors. What is the effect of GH treatment alone in peri-puberty? Past literatures are not accurate. This is the first multicenter study in China on the efficacy of growth hormone alone in the treatment of elder children. In our current study, we followed up children with ISS diagnosed by the departments of pediatric endocrinology in seven tertiary hospitals in different regions of mainland China, and evaluated the efficacy of GH for ISS children until FAH.

---

### Effects of different therapy regimens to increase final adult height in males at advanced bone age with idiopathic short stature [^112wQhuZ]. BMC Pediatrics (2023). Medium credibility.

Introduction

Recombinant human growth hormone (rhGH) therapy is the most effective treatment for idiopathic short stature (ISS) in children. When given to prepubertal children, rhGH can successfully increase the growth velocity and adult height. However, due to early puberty onset and (or) delayed initial consultation, some adolescent children with ISS experience accelerated linear bone growth at the time of treatment. It is generally agreed that an advanced stage of bone age in pubescent boys limits the application window in which to treat with rhGH. Thus, to maximize the adult height (AHt), endocrinologists have sought therapeutic alternatives to delay bone maturation and epiphyseal fusion.

Estrogen is a well-known regulator of endochondral bone growth and plays an essential role in controlling longitudinal bone growth during puberty by promoting the closure of the epiphyses. GnRHa, which promotes the regression of sexual characteristics by competing for receptors and inhibiting gonadotropin secretion, can effectively delay bone maturation and improve the adult height achieved by children. However, blocking estrogen production might delay epiphyseal fusion, potentially leading to a prolonged period of longitudinal growth and an increased final AHt. Aromatase inhibitors (AIs) block the activity of the aromatase enzyme CYP 19, which promotes the production of estrogen from androgens. Several studies have suggested that monotherapy with GnRHa or AIs can have a small and variable effect on adult height for short stature at advanced bone age and is generally not recommended. However, combination therapy with rhGH and GnRHa or rhGH and AIs has potential value. Additionally, whether the AHt can reach the normal range after therapy is considered the gold standard for evaluating therapy efficacy. However, to date, few clinical studies have been published. The primary purpose of this study was to explore the effect of different treatments on increasing the AHt of boys at advanced bone age with ISS.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^117US7Vv]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) — dose–response evidence indicates that in the only study of dose effect with an untreated control group, in ISS per protocol subjects the difference in gain in HtSDS between 0.23 and 0.47 mg/kg/week (33 and 67 μg/kg/day) was nonsignificant, and was borderline significant (p = 0.056) in the combined ISS and small for gestational age (SGA) group. Another comparison without untreated controls in 239 children reported dosing of 0.24 mg/kg/week, 0.24 for the first year then 0.37 mg/kg/week thereafter, or 0.37 mg/kg/week with mean HtSDS changes from baseline of 1.55 ± 0.14, 1.52 ± 0.27, and 1.85 ± 0.2, respectively, with statistical testing not performed between groups.

---

### The effect of growth hormone treatment on height in children with idiopathic short stature [^114i4K7C]. Journal of Pediatric Endocrinology & Metabolism (2014). Low credibility.

Background

Idiopathic short stature (ISS) is short stature of unknown cause. In 2003, the Food and Drug Administration (FDA) approved the use of growth hormone (GH) for ISS. Several studies have evaluated the effect of GH in children with ISS, in whom improved growth velocities and height standard deviation scores (SDS) have been reported. However, clinical variables influence the height improvement.

Objective

This study aimed to evaluate the effects of GH treatment on ISS and to analyze clinical factors associated with growth velocity.

Materials and Methods

This study was conducted retrospectively. Subjects diagnosed with ISS at Ajou University Hospital were divided into two groups, an ISS with GH-treatment group (n = 34) and an ISS control group (n = 36). All children were prepubertal, and aged < 10 years. We reviewed their auxological data, laboratory findings, and bone age.

Results

Growth velocity of the GH-treatment group exceeded that of controls by 3.37 cm/year (95% CI, 2.78–3.95). At baseline, the mean SDS for height in the treatment and control groups were equivalent (-2.25 ± 0.29 and -2.22 ± 0.31, respectively). However, after 1 year, the height of the GH-treated group exceeded that of the control group by 0.73 SDS (95% CI, 0.57–0.88). A negative correlation was found between age and growth velocity in the GH-treatment group.

Conclusion

GH treatment increased short-term growth velocity and height SDS of Korean children with ISS. Age was identified as the single most important factor correlated with growth velocity in GH treatment.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^111rrtyG]. BMC Pediatrics (2025). Medium credibility.

Objective

To explore the effect of short-acting growth hormone (GH) supplementation on bone age and growth rate of children with idiopathic short stature.

Methods

The authoritative databases such as PubMed, Medline, and Web of Science were extensively searched through the systematic and comprehensive literature retrieval strategy to compile the clinical research data on the treatment of idiopathic short stature with short-acting GH. The study will be strictly screened to ensure that all enrolled research subjects are patients with idiopathic short stature, and the intervention method is defined as short-acting GH replacement therapy, and a reasonable control group is set, such as placebo treatment, to ensure the scientificity and comparability of research results. Outcome index data such as basic characteristics, sample size, follow-up time, and total effective rate of the included studies were extracted. In this study, RevMan 5.3, a professional statistical software tool, was used to systematically perform the meta-analysis process. Weighted average difference (WMD) was calculated as the primary outcome to evaluate the effect of bone age and growth rate, and the WAD in adverse reactions was considered as the secondary outcome.

Results

Nine studies were included in the study, and 491 patients with idiopathic short stature were included in the study. The results of the meta-analysis showed that there was no significant difference in bone age but a significant difference in growth rate when compared with the control group.

Conclusion

Short-acting GH supplementation can significantly improve the growth rate of children with idiopathic short stature, but has little effect on bone age.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12887-024-05356-z.

---

### Idiopathic short stature: a clinical review [^114kLYCP]. JAMA (2014). Excellent credibility.

Importance

Approximately 2% of children are defined as having short stature. Deciding when to pursue recombinant human growth hormone therapy to increase adult height is controversial.

Objective

To review the management of children with idiopathic short stature, including diagnostic evaluation and therapeutic options.

Evidence Review

Systematic literature search of PubMed, Embase, and the Cochrane Library databases. For height outcome, articles were limited to studies reporting adult height and to systematic reviews.

Findings

Recombinant human growth hormone therapy of children with idiopathic short stature increases height in some children. The estimated mean gain in adult height is 5.2 cm (2 in). The cost-benefit ratio is controversial. Treatment with growth hormone appears safe in the short term, while data on long-term effects are limited because studies of long-term efficacy were not powered to determine safety.

Conclusions and Relevance

Growth hormone treatment may be considered in some children with idiopathic short stature.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^113q8ALR]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone and insulin-like growth factor-I therapeutics — emerging products and research needs note newer options such as bioequivalent GH products and a combined GH/IGF-I product, continued interest in an effective sustained-release GH preparation to reduce injection frequency, and reports suggesting potential benefit of GH in some non-FDA-approved indications; given unanswered questions and an evolving field, the document states that further study of unresolved issues is recommended.

---

### Growth hormone use in children with idiopathic short stature [^113iaLZ8]. The Annals of Pharmacotherapy (2004). Low credibility.

Objective

To review the indication, pharmacology, pharmacokinetics, efficacy, and adverse effects of recombinant human growth hormone in children with idiopathic short stature (ISS).

Data Sources

A MEDLINE search (1966-December 2003) was performed using the key words human growth hormone, somatropin, Humatrope, normal children, somatrem, and idiopathic short stature. Food and Drug Administration Advisory Committee Meeting minutes were also reviewed.

Study Selection and Data Extraction

The data presented in this review were obtained from published literature, abstracts presented at scientific meetings, and information on file with the manufacturer. Additional articles from these sources were also identified. Current issues of pediatric and endocrinology journals were reviewed for the most recent articles. Articles only addressing the use of growth hormone in normal, healthy children were used.

Data Synthesis

Somatropin is indicated for use in children with ISS. Studies have shown modest benefit to final height achieved and, at the doses used for ISS, there have been no adverse effects associated with somatropin. Many questions still exist, however, concerning the most appropriate age to initiate treatment and duration of treatment. There are also many ethical concerns surrounding patient selection criteria and potential for increased off-label use.

Conclusions

Growth hormone has been found to have modest efficacy in improving final height in children with ISS. The specific patient population likely to achieve maximal benefit, optimal dosage regimens, and the long-term adverse effects of extended duration of therapy are unknown.

---

### Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature [^116mbZPU]. The Journal of Clinical Endocrinology and Metabolism (2005). Low credibility.

Context

Small clinical trials of GH treatment of idiopathic short stature (ISS) show variable efficacy.

Objective

The study was an analysis of a large GH registry for efficacy and safety of GH treatment of ISS. There was also a comparison with a specific clinical trial.

Design

Up to 7 yr of GH treatment of ISS was evaluated for efficacy and safety in the National Cooperative Growth Study (NCGS).

Setting

The NCGS study was conducted at Genentech, Inc. and included 47,226 patients.

Patients

The ISS group included maximum stimulated GH 10 ng/ml or more and/or a report of ISS by investigator (n = 8018; all included for safety). Cohort 1 (n = 2520) was similar to the clinical trial, cohort 2 (n = 283) included subjects younger than 5 yr of age, and cohort 3 (n = 940) was pubertal at GH start.

Intervention

GH, approximately 0.30 mg/kg.wk, was given.

Main Outcome Measures

These included growth velocities and height sd (HtSDS).

Results

Mean first-year growth velocities in cohorts 1, 2, and 3 increased 4.6, 3.9, and 4.4 cm/yr over pretreatment, respectively. Measures included: baseline mean HtSDS, -2.9, -3.2, and -2.8; mean HtSDS at 1 yr, -2.4, -2.3, and -2.3, respectively. Mean HtSDS after 7 yr in cohorts 1 (n = 303) and 2 (n = 85) and 5 yr in cohort 3 (n = 58) were: -1.2, -1.0, and -1.5, respectively. Cohort 3 shorter treatment time was due to advanced baseline age (mean 13.8 yr) and puberty. Mean HtSDS gain in cohort 1 was comparable with the clinical trial. No new safety signals specific to the NCGS ISS population were observed.

Conclusion

ISS patients in the GH registry demonstrate a significant increase in HtSDS with the safety profile similar to GH-deficient patients. RESULTS were similar to the clinical trial.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^116NrvYV]. BMC Pediatrics (2025). Medium credibility.

Exclusion criteria

Excluded articles that had either of the following: (1) Articles that were not associated with idiopathic short stature or that referred only to idiopathic short stature but did not undergo a specific study. (2) Articles that do not use short-acting GH supplementation as an intervention, such as articles that only use other GH supplementation. (3) Multiple articles with repeated publication or overlapping data in the same study are required to avoid bias of study results. (4) Articles for which full-text or key data were not available were excluded to ensure the completeness and accuracy of research data.

Search strategy

Database

(1) PubMed (2) Web of Science (3) Cochrane Library (4) Embase (5) CNKI.

English search terms

(1) In the actual search of "idiopathic short stature" (2) "short-acting growth hormone" (3) "bone age" (4) "growth rate", the search terms are combined AND adjusted according to the specific requirements, and the search strategy is optimized by using Boolean logic operators (such as AND and OR) to obtain more accurate and comprehensive literature results. For example: "idiopathic short stature" AND "short-acting growth hormone" AND "bone age". " Idiopathic short statur"AND"Short acting growth hormone"AND"Bone Age". The retrieval time was from the establishment of each database to July 2024.

Literature screening and data extraction

Literature screening was carried out independently by two researchers. Firstly, obviously irrelevant literature was excluded based on the titles and abstracts. For the potentially relevant literature, the full texts were obtained for further evaluation. The extracted information included: basic information of the studies (authors, publication year, research location, etc.), patient characteristics (age, gender, course of the disease, etc.), intervention measures (such as short-acting growth hormone supplementation), control measures (such as placebo), outcome indicators, follow-up time, etc.

Literature quality evaluation

The Cochrane risk assessment tool for bias was used for literature quality evaluation. Aspects of evaluation included random sequence generation, allocation concealment, blinded implementation, integrity of outcome data, selective reporting of study results, and other sources of bias. Conclusions from the quality evaluation, such as low-risk, high-risk or unclear, were presented for each included article.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^1144Wtaj]. Hormone Research in Paediatrics (2016). Medium credibility.

Insulin-like growth factor-I (IGF-I) dosing — comparative outcomes and dose suggestion: In a trial, fourteen received 120 μg/kg b.i.d. while 7 received 80 μg/kg b.i.d., and the higher dose group showed accelerated skeletal maturation in the third year with increased percent body fat and adrenal growth; in the absence of hard evidence for greater benefit of the higher dose, the authors conditionally suggest use of the lower dose.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112fWVV2]. Hormone Research in Paediatrics (2016). Medium credibility.

General recommendations — We recommend that physicians with expertise in managing endocrine disorders in children manage or provide consultation for the evaluation for GHD-ISS-PIGFD and treatment thereof, and we recommend further study of the unresolved issues highlighted in these guidelines.

---

### Growth hormone for treatment of idiopathic short stature in children… [^1151WqWZ]. AAFP (2025). Medium credibility.

Clinical Question Is recombinant growth hormone effective in the treatment of idiopathic short stature in children. Evidence-Based Answer Final adult height is modestly increased in children who receive rGH, with growth increases of 3. 5 to
7. 5 cm. However, the use of rGH does not improve health-related quality of life. A Cochrane review examined the effect of treatment with rGH vs. no treatment or placebo in 741 children with height less than the 3rd percentile who had no apparent underlying pathology. 1 One trial found that the nearfinal height in 10 pubertal girls who received 30 IU of rGH per m 2 per week for three years was 7. 5 cm greater than that in 30 untreated girls. Another trial that reported adult height found that 37 children who received rGH were 3.

7 cm taller than those in the placebo group. The remaining eight trials reported short-term height gains, which varied from none to 0. 7 standard deviations in a year. One study that reported health-related quality of life found no significant improvement in 20 children who received rGH compared with 20 children in a control group. The quality of the studies was rated as moderate for two, poor for six, and very poor for two. A systematic review included only trials that evaluated adult height. 2 Participants had a growth velocity of less than 1. 5 cm per year or a bone age of 15 years in females or 16 years in males. The treatment group in the RCTs received 0. 033 to
0. 067 mg of rGH per kg per day. The adult height of the treated group exceeded that of the control group, with a mean difference of 0. 65 standard deviations.

In the seven nonrandomized trials, the mean adult height of treated children exceeded that of the control group by a mean difference of 0. 45 standard deviations. Eight of the studies were rated low quality because of a high percentage of dropouts, and two of the RCTs were rated moderate quality. In 2008, 32 leaders in the field of idiopathic short stature published a consensus statement based on a review of the literature and clinical experience. 3 The consensus was that rGH therapy following country-specific regulatory guidelines is appropriate, and that stronger consideration should be given to shorter children. The mean increase in adult height with rGH therapy is 3. 5 to
7. 5 cm. Copyright Family Physicians Inquiries Network. Used with permission.

---

### Early growth hormone initiation leads to favorable long-term growth outcomes in children born small for gestational age [^1163doUY]. The Journal of Clinical Endocrinology and Metabolism (2023). Medium credibility.

Growth hormone (GH) therapy is widely used for the treatment of short stature in children with a number of disorders, including GH deficiency (GHD), Turner syndrome, Prader-Willi syndrome, Noonan syndrome, idiopathic short stature (ISS), chronic renal failure, short stature homeobox containing gene deficiency, and short children born small for gestational age (SGA). According to consensus guidelines, newborns with a birth weight and/or length standard deviation score (SDS) of < −2 for gestational age are considered SGA. Although most infants born SGA show early spontaneous catch-up growth, short stature persists into childhood and adulthood in approximately 10% of patients. GH therapy is approved for the treatment of children born SGA who fail to show spontaneous catch-up growth by 2 to 4 years of age in the USA, or by 4 years of age or later in Europe. The effectiveness of GH treatment for improving growth outcomes in children born SGA has been well documented.

A consensus statement on the management of short children born SGA recommends starting GH therapy at a young age, and in patients born SGA with Silver–Russell syndrome, initiation of GH treatment at age 2 to 4 years is recommended. However, real-world data indicate that the initiation of GH treatment in SGA patients is often delayed. In the observational NordiNet ® International Outcome Study (IOS), the mean age at GH treatment start was 8.5 years in France, 7.7 years in Germany, and 7.1 years in the UK. Early age at GH treatment initiation has been shown to be an important predictor of growth response in patients born SGA and there is evidence that starting GH therapy at an early age is associated with improved height outcomes. Accordingly, greater gains in height standard deviation score (HSDS) have been observed among GH-treated children born SGA aged < 4 years compared with older patients.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^111sng1t]. Hormone Research in Paediatrics (2016). Medium credibility.

Growth hormone deficiency (GHD) during the transition period — We suggest that GH treatment be offered to individuals with persistent GHD in the transition period, although the specifics of who benefits, timing, and optimal dose are not clear. The transition period is described as the time from late puberty to establishment of adult muscle and bone composition and encompasses attainment of adult height (AH). Evidence includes three RCTs in young adults with persistent GHD in which 2 years of GH treatment increased bone mineral density, normalized insulin-like growth factor-I (IGF-I) levels, and improved lipid profiles from baseline, while a fourth RCT did not demonstrate differences after 2 years. Across studies, the duration of GH was 1–6 years and the average age at re‑initiation was 18–23 years with a range of 15–35 years; one study had an average age at transition of 16 years and a 1 month period off pediatric GH by design. Dosing used in RCTs varied from 12.5 to 25 μg/kg/day to 200 μg/day, and adult guidance suggests patients < 30 years may benefit from initial doses of 400–500 μg daily versus 200–300 μg daily for patients aged 30–60 years; those transitioning from pediatric to adult replacement and females receiving oral estrogen (but not transdermal) may need higher doses, and doses subsequently should be titrated to normalize the serum IGF‑I concentration for age and gender.

---

### Growth hormone therapy for a child with severe cognitive impairment [^1117hKSk]. Pediatrics (2018). Low credibility.

The expansion of growth hormone therapy over the last 3 decades has allowed for treatment of short stature for more children, resulting in increased height for many. However, treatment of idiopathic short stature remains controversial. Treatment decisions for disabled children with idiopathic short stature are even more complicated. We discuss a specific case of short stature in a disabled child and grapple with the ethical issues involved in the use of growth hormone.

---

### Somatropin (omnitrope) [^111pHZTA]. FDA (2025). Medium credibility.

14.5 Idiopathic Short Stature (ISS)

The long-term efficacy and safety of another somatropin product in patients with idiopathic short stature (ISS) were evaluated in one randomized, open-label, clinical trial that enrolled 177 children. Patients were enrolled on the basis of short stature, stimulated GH secretion > 10 ng/mL, and prepubertal status (criteria for idiopathic short stature were retrospectively applied and included 126 patients). All patients were observed for height progression for 12 months and were subsequently randomized to this other somatropin product or observation only and followed to final height. Two somatropin doses were evaluated in this trial: 0.23 mg/kg/week (0.033 mg/kg/day) and 0.47mg/kg/week (0.067 mg/kg/day). Baseline patient characteristics for the ISS patients who remained prepubertal at randomization (n = 105) were: mean (± SD): chronological age 11.4 (1.3) years, height SDS -2.4 (0.4), height velocity SDS -1.1 (0.8), and height velocity 4.4 (0.9) cm/yr, IGF-1 SDS -0.8 (1.4). Patients were treated for a median duration of 5.7 years. Results for final height SDS are displayed by treatment arm in Table 9. Therapy with this other somatropin product improved final height in ISS children relative to untreated controls. The observed mean gain in final height was 9.8 cm for females and 5.0 cm for males for both doses combined compared to untreated control subjects. A height gain of 1 SDS was observed in 10% of untreated subjects, 50% of subjects receiving 0.23 mg/kg/week and 69% of subjects receiving 0.47 mg/kg/week.

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^112qrAyw]. Hormone Research in Paediatrics (2016). Medium credibility.

Idiopathic short stature (ISS) management — In the USA, for children who meet FDA criteria, we suggest a shared decision‑making approach to pursuing growth hormone (GH) treatment for a child with ISS, and we recommend against the routine use of GH in every child with height standard deviation score (HtSDS) less than −2.25. We suggest a follow‑up assessment of benefit in HtSDS and psychosocial impact 12 months after GH initiation and dose optimization. GH increases adult height (AH) in some children with ISS; ISS is heterogeneous and includes familial ISS and nonfamilial ISS, both with and without pubertal delay, and genetic disorders affecting the growth plate such as SHOX and NPR2 defects must be excluded with attention to body proportions. Patients with ISS and their families should be counseled that responses vary and that, on average, there will be an approximately 5‑cm (2‑inch) increase in AH.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^114Q86gd]. BMC Pediatrics (2020). Medium credibility.

Results

General data

Among the 344 ISS patients in seven centers, there were 217 boys and 127 girls. The average age of boys and girls when starting the treatment (baseline) was 12.7 ± 1. 87 and 11.7 ± 1.61 years, with bone age of 11.7 ± 2.32 years and 10.1 ± 2.03 years, respectively. The growth stopped at the final follow-up visit, with a mean age of 18.5 ± 2.25 years for boys and 18.0 ± 2.02 years for girls (Table 1).

Table 1
General data

The baseline height SDS of boys and girls was − 3.07 and − 2.74, and the FAH SDS was − 1.91 and − 1.38, respectively. Compared with the baseline height SDS, the FAH SDS was significantly increased in both boys and girls (both P = 0.0000) (Table 1).

---

### Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency [^116WxnEF]. Hormone Research in Paediatrics (2016). Medium credibility.

IGF-I dosing — We suggest an IGF-I dose of 80–120 μg/kg b.i.d., noting that similar short-term outcomes were seen with 80 and 120 μg and there is no strong evidence supporting superiority of one dose over the other; outside of the USA, IGF-I is also used at 150–180 μg/kg once daily.

---

### High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature [^112tQUhJ]. Archives of Disease in Childhood (2002). Low credibility.

Background

Long term growth hormone (GH) treatment in children with idiopathic short stature (ISS) results in a relatively small mean gain in final height of 3–9 cm, which may not justify the cost of treatment. As it is unknown whether GH treatment during puberty adds to final height gain, we sought to improve the cost-benefit ratio, employing a study design with high dose GH treatment restricted to the prepubertal period.

Aims

To assess the effect of short term, high dose GH treatment before puberty on growth, bone maturation, and pubertal onset.

Methods

Five year results of a randomised controlled study are reported. Twenty six boys and nine girls were randomly assigned to a GH treatment group (n = 17) or a control group (n = 18). Inclusion criteria were: no signs of puberty, height less than -2 SDS, age 4–8 years for girls or 4–10 years for boys, GH concentration > 10 micro g/l after provocation, and normal body proportions. To assess GH responsiveness, children assigned to the GH treatment group received GH treatment for two periods of three months (1.5 IU/m2/day and 3.0 IU/m2/day), separated by three month washout periods, during the first year of study. High dose GH treatment (6.0 IU/m2/day) was then started and continued for at least two full years. When puberty occurred, GH treatment was discontinued at the end of a complete year's treatment (for example, three or four years of GH treatment).

Results

In response to at least two years on high dose GH treatment, mean (SD) height SDS for chronological age increased significantly in GH treated children from -2.6 (0.5) to -1.3 (0.5) after two years and -1.4 (0.5) SDS after five years of study. No changes in height SDS were observed in controls. A rapid rate of bone maturation of 3.6 years/2 years in treated children compared to 2 years/2 years in controls was observed in response to two years high dose GH treatment. Height SDS for bone age was not significantly different between groups during the study period. GH treated children entered into puberty at a significantly earlier age compared to controls.

Conclusions

High dose GH treatment before puberty accelerates bone age and induces an earlier onset of puberty. This may limit the potential therapeutic benefit of this regimen in ISS.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^112Nmy47]. BMC Pediatrics (2020). Medium credibility.

Methods

A real-world observation was carried out. Clinical data including name, sex, date of birth, age at baseline, baseline height, baseline bone age based on Greulich-Pyle methodology, GH treatment course, age at last follow-up, FAH, and parents' heights were recorded. The baseline height SD score (SDS), FAH SDS, and target height (TH) SDS were calculated. GH was subcutaneously injected at a dose of 0.15–0.2 IU/kg/day.

The height SD score (HtSDS) was calculated by referring to the 2005 Standard Deviations of Height and Weight for Children and Adolescents Aged 0–18 years in China.

Height standard deviation score (HtSDS) = (actual height − average height for children of the same sex and age) ÷ (SD of the heights for children of the same sex and age).

TH (i.e. mid-parental target height) was as follows:

FAH was defined as follows: age at the last follow-up was > 15 years, height velocity was below 1 cm/year, and the GH therapy had been discontinued.

The primary endpoint was the difference between FAH SDS and baseline height SDS, i.e. the height SDS gain, expressed as △1HtSDS. The secondary endpoint was the difference between FAH SDS and TH SDS, i.e. the height gain over the TH (△2HtSDS). △3HtSDS is baseline height SDS minus TH SDS. In addition, influencing factors of height SDS were analyzed.

The control group comprised patients who had been treated for less than 3 months. The remaining patients were divided into the 3–6 m group (treated for 3–6 months), 6–12 m group (treated for 6 months to 1 year), 1–2y group (treated for 1–2 years), and ≥ 2y group (treated for 2 or more years).

Patients were also stratified according to gender.

Screening flowchart:

Statistical analysis

Statistical analysis was performed using SPSS 20.0 software. A normal distribution test showed that all measurement data were normally distributed. Data are presented as mean ± SD. The means of two independent samples were compared by using the t test, and the comparisons of means among multiple groups were based on analysis of variance. The influencing factors of FAH SDS were analyzed by multivariate linear regression. A P value of less than 0.05 was considered significantly different.

---

### Effect of growth hormone therapy on height in children with idiopathic short stature… [^112BJccC]. JAMA Network (2002). Excellent credibility.

Results of individual controlled trials of growth hormone therapy for idiopathic short stature included in the meta-analysis. A, Mean ± SE difference in growth velocity between treatment and control groups at baseline and after 1 year. B, Mean difference in height SD scores between treatment and control groups for predicted adult height and achieved adult height. Asterisk indicates that no measure of variation was provided for predicted adult height in this study; therefore, it was not included in the analysis of differences between treatment and control groups. Results of individual uncontrolled trials of growth hormone therapy for idiopathic short stature included in the meta-analysis. For a complete listing of author names, reference citation, and study year, see Table 3. A, Mean ± SE growth velocity at baseline and after 1 year.

Asterisk indicates that this study addressed the effect of growth hormone treatment in older children during the decelerating phase of the pubertal growth spurt. B, Mean adult height SD scores predicted at baseline and achieved. We performed a meta-analysis of all studies satisfying the inclusion criteria for idiopathic short stature: initial height below the 10th percentile, normal stimulated GH levels, absence of comorbid conditions, no previous GH therapy, treatment with biosynthetic GH, and inclusion of major outcome measures. Primary Outcome Measures. Ten controlled trials and 28 uncontrolled trials met the inclusion criteria. While baseline growth velocities were equivalent at baseline, 1-year growth velocity of the GH-treated group significantly exceeded that of controls by 2. 86 cm/y. Similarly, in uncontrolled trials, growth velocity increased after 1 year, and height SD score increased from −2. 72 at baseline to −2.
19.

In controlled studies, the adult height of the GH-treated group significantly exceeded controls by 0. 84 SD, and in uncontrolled trials the adult height attained after GH treatment exceeded that predicted at baseline. These results suggest an average gain in adult height of approximately 4 to 6 cm with GH therapy. Given current treatment costs, this corresponds to more than $35 000 per inch gained in adult height in idiopathic short stature. Conclusions Treatment with GH results in short-term increases in growth for children with idiopathic short stature, and long-term GH can increase adult height. These results are fundamental to decisions about GH use and raise questions about the goals of treatment. Use of GH for idiopathic short stature in clinical practice will depend on its efficacy in promoting growth and the value of this effect to families, physicians, and third-party payers.

The weighted pooled estimate for age at baseline was 10. 1 ±
0. 6 years in the treatment group and 9. 8 ±
0. 7 years in the control group. Growth variables reported in each of the studies are given in Table 1. Table 2 gives the results of the meta-analysis for controlled studies of idiopathic short stature. The short-term effects of GH treatment on growth velocity and height SD score were assessed, as were the long-term effects of GH on adult height; these are the primary outcome measures. Results for each growth variable are expressed as the pooled estimate of the difference between the treatment and control groups. Baseline pretreatment growth velocities of treatment and vcontrol groups were equivalent, with respective mean baseline growth rates of 4. 22 ±
0. 21 and 4. 30 ±
0. 25 cm/y.

---

### The role of recombinant human insulin-like growth factor-I in treating children with short stature [^115QubwA]. The Journal of Clinical Endocrinology and Metabolism (2008). Medium credibility.

Growth hormone deficiency (GHD) definitions and expected growth response to rhGH are quantified. When stimulated GH levels of less than 10 ng/ml are used to define GHD, more than 30% of children have a growth increment of less than 0.5 SD score (SDS) in the first year of therapy. Children with short stature, delayed bone age, low serum IGF-I, and normal or elevated GH are not considered GH deficient.

---

### Somatropin (Genotropin) [^114GKEfh]. FDA (2025). Medium credibility.

14.5	Idiopathic Short Stature

The long-term efficacy and safety of GENOTROPIN in patients with idiopathic short stature (ISS) were evaluated in one randomized, open-label, clinical trial that enrolled 177 children. Patients were enrolled on the basis of short stature, stimulated GH secretion > 10 ng/mL, and prepubertal status (criteria for idiopathic short stature were retrospectively applied and included 126 patients). All patients were observed for height progression for 12 months and were subsequently randomized to GENOTROPIN or observation only and followed to final height. Two GENOTROPIN doses were evaluated in this trial: 0.23 mg/kg/week (0.033 mg/kg/day) and 0.47 mg/kg/week (0.067 mg/kg/day). Baseline patient characteristics for the ISS patients who remained prepubertal at randomization (n = 105) were: mean (± SD): chronological age 11.4 (1.3) years, height SDS -2.4 (0.4), height velocity SDS -1.1 (0.8), and height velocity 4.4 (0.9) cm/yr, IGF-1 SDS -0.8 (1.4). Patients were treated for a median duration of 5.7 years. Results for final height SDS are displayed by treatment arm in Table 7. GENOTROPIN therapy improved final height in ISS children relative to untreated controls. The observed mean gain in final height was 9.8 cm for females and 5.0 cm for males for both doses combined compared to untreated control subjects. A height gain of 1 SDS was observed in 10% of untreated subjects, 50% of subjects receiving 0.23 mg/kg/week and 69% of subjects receiving 0.47 mg/kg/week.

---

### Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children [^115zc45A]. Journal of Pediatric Endocrinology & Metabolism (2017). Low credibility.

Background

In recent years, several studies have been published showing different responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of the present study was to investigate whether non-growth-hormone-deficient (non-GHD) short children could benefit from long-term GH treatment as GHD patients.

Methods

We enrolled 22 prepubertal children and 22 age- and sex-matched GHD patients, with comparable height, body mass index (BMI), bone age, and insulin-like growth factor 1 (IGF-I) circulating levels. The patients were treated with recombinant human GH (rhGH) and followed until they reach adult height.

Results

During GH treatment, the two groups grew in parallel, reaching the same final height-standard deviation score (SDS) and the same height gain. On the contrary, we found significantly lower IGF-I serum concentrations in non-GHD patients than in GHD ones, at the end of therapy (p = 0.0055).

Conclusions

In our study, the response to GH treatment in short non-GHD patients proved to be similar to that in GHD ones. However, a careful selection of short non-GHD children to be treated with GH would better justify the cost of long-term GH therapy.

---

### Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis [^113daf8k]. BMC Pediatrics (2025). Medium credibility.

This article did not conduct a sensitivity analysis to evaluate the robustness of the results of different subgroups (such as age, gender, treatment time), nor did it elaborate on details like demographics. This is because the number of included literature was small and insufficient literature was retrieved for analysis. Future studies can conduct deeper excavation and screening of the existing research results to evaluate the robustness of the results of different subgroups more comprehensively and accurately, supplement the research details, and provide more powerful evidence for the reliability of the research conclusions.

---

### Somatropin (Humatrope) [^116WM2sC]. FDA (2025). Medium credibility.

14.3 Pediatric Patients with Idiopathic Short Stature (ISS)

Two randomized, multicenter studies, one placebo-controlled and one dose-response, were conducted in pediatric patients with idiopathic short stature. The diagnosis of idiopathic short stature was made after excluding other known causes of short stature, as well as GH deficiency. The placebo-controlled study enrolled 71 pediatric patients (55 males, 16 females) 9 to 15 years old (mean age 12.4 ± 1.5 years), with short stature, 68 of whom received placebo (n = 31) or HUMATROPE (n = 37); NCT00191074. Patients were predominately prepubertal (Tanner I, 45%) or in early puberty (Tanner II, 47%) at baseline. In this double-blind study, patients received subcutaneous injections of either HUMATROPE 0.222 mg/kg/week, or placebo given in divided doses 3 times per week until height velocity decreased to ≤ 1.5 cm/year ("final height"). Final height measurements were available for 33 subjects (22 treated with HUMATROPE, 11 treated with placebo) after a mean treatment duration of 4.4 years (range 0.1–9.1 years).

Results are presented in Table 11. The number of patients whose final height was above the 5th percentile of the general population height standard for age and sex was significantly greater in the HUMATROPE group than the placebo group (41% vs. 0%), as was the number of patients who gained at least 1 SDS unit in height across the duration of the study (50% vs. 0%).

---

### The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis [^113pJCC2]. Journal of Pediatric Endocrinology & Metabolism (2020). Medium credibility.

Objectives

Idiopathic short stature (ISS) is a recognized, albeit a controversial indication for treatment with recombinant human growth hormone (rhGH). The objective of the present study was to conduct a systematic review of the literature and meta-analyses of selected studies about the use of rhGH in children with ISS on linear growth and adult height (AH).

Methods

A systematic literature search was conducted to identify relevant studies published till February 28, 2017 in the following databases: Medline (PubMed), Scopus and Cochrane Central Registry of Controlled Trials. After exclusion of duplicate studies, 3,609 studies were initially identified. Of those, 3,497 studies were excluded during the process of assessing the title and/or the abstract. The remaining 112 studies were evaluated further by assessing the full text; 21 of them fulfilled all the criteria in order to be included in the current meta-analysis.

Results

Children who received rhGH had significantly higher height increment at the end of the first year, an effect that persisted in the second year of treatment and achieved significantly higher AH than the control group. The difference between the two groups was equal to 5.3 cm (95% CI: 3.4–7 cm) for male and 4.7 cm (95% CI: 3.1–6.3 cm) for female patients.

Conclusion

In children with ISS, treatment with rhGH improves short-term linear growth and increases AH compared with control subjects. However, the final decision should be made on an individual basis, following detailed diagnostic evaluation and careful consideration of both risks and benefits of rhGH administration.

---

### Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty [^114NqNwV]. BMC Pediatrics (2020). Medium credibility.

Our study showed that 54.4% of boys and 78.7% of girls had a FAH SDS > −2SD after GH treatment. This result explains that GH therapy is effective even in peri-puberty children. Among the girls who had been treated with GH > 2 years, their FAH was higher than TH. This further confirmed that GH therapy could improve FAH and longer the better. For boys, FAH SDS was lower than TH SDS in all groups although they attained the normal height. It may be that boys need to improve their height longer than girls. In the GeNeSIS observation study by Pfäffle and colleagues, including United States, Germany and France data, shows that most children achieved near adult height (NAH) within the normal range (height SDS > − 2) after GH treatment. The main population of our study is Chinese Han children. It shows that the same results as in Europe and America, the efficacy of growth hormone is similar.

The average age of boys and girls at baseline was 12.7 ± 1.87 years and 11.7 ± 11.7 years, with bone age of 11.7 ± 2.32 years and 10.1 ± 10.02 years, respectively. The relatively late initiation of treatment reflected the real-world situation. Multivariate linear regression model analysis showed that FAH is influenced positively by baseline height SDS in the boys and girls, whereas negatively by baseline bone age in girls, which was consistent with previous findings. Many previous studies have demonstrated that the age when starting GH treatment is an important factor for its efficacy. In this regard, our patients might have benefited more from GH therapy if the treatment had started earlier.

And we notice in this study, even in the control group, there is a spontaneous height gain of 1.16 SD. Economic factors need to be taken into account in the treatment of ISS. In China, growth hormone therapy for ISS is covered by families themselves. Whether to treatment or not, as well as the course of treatment, is decided by parents after weighing the family economic and height expectations.

This study had some limitations: Although it was a multi-center observation study, 344 of 475 cases entered the final analysis. It reflects "real-world" clinical practice and can be considered reliable, but which is not represented in random clinical trials. The sample is not big enough when stratification by treatment duration, if there is a larger sample in each subgroup, it will be better to validate our findings.